Matrix-regulated integrin $\alpha_v\beta_5$ maintains $\alpha_5\beta_1$-dependent desmoplastic traits prognostic of neoplastic recurrence

Janusz Franco-Barraza¹, Ralph Francescone¹, Tiffany Luong¹, Neelima Shah¹, Raj Madhani¹, Gil Cukierman¹, Essel Dulaimi², Karthik Devarajan³, Brian L Egeston⁴, Emmanuelle Nicolas⁵, R Katherine Alpaugh⁶, Ruchi Malik¹, Robert G Uzzo¹,⁷, John P Hoffman⁷, Erica A Golemis⁴, Edna Cukierman*¹

¹Department of Cancer Biology, Fox Chase Cancer Center, Philadelphia, United States; ²Department of Pathology, Fox Chase Cancer Center, Philadelphia, United States; ³Department of Cancer Epigenetics, Fox Chase Cancer Center, Philadelphia, United States; ⁴Department of Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, United States; ⁵Programs in Genomics, Fox Chase Cancer Center, Philadelphia, United States; ⁶Protocol Support Lab, Fox Chase Cancer Center, Philadelphia, United States; ⁷Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, United States

Abstract Desmoplasia, a fibrotic mass including cancer-associated fibroblasts (CAFs) and self-sustaining extracellular matrix (D-ECM), is a puzzling feature of pancreatic ductal adenocarcinoma (PDACs). Conflicting studies have identified tumor-restricting and tumor-promoting roles of PDAC-associated desmoplasia, suggesting that individual CAF/D-ECM protein constituents have distinguishable tumorigenic and tumor-repressive functions. Using 3D culture of normal pancreatic versus PDAC-associated human fibroblasts, we identified a CAF/D-ECM phenotype that correlates with improved patient outcomes, and that includes CAFs enriched in plasma membrane-localized, active $\alpha_5\beta_1$-integrin. Mechanistically, we established that TGF$\beta$ is required for D-ECM production but dispensable for D-ECM-induced naïve fibroblast-to-CAF activation, which depends on $\alpha_v\beta_5$-integrin redistribution of pFAK-independent active $\alpha_5\beta_1$-integrin to assorted endosomes. Importantly, the development of a simultaneous multi-channel immunofluorescence approach and new algorithms for computational batch-analysis and their application to a human PDAC panel, indicated that stromal localization and levels of active SMAD2/3 and $\alpha_5\beta_1$-integrin distinguish patient-protective from patient-detrimental desmoplasia and foretell tumor recurrences, suggesting a useful new prognostic tool.

DOI: 10.7554/eLife.20600.001

Introduction

The mesenchymal stroma typically found in normal tissues, which is composed mainly of naïve quiescent fibroblastic cells and their secreted interstitial extracellular matrix (ECM), constitutes a natural tumor suppressive microenvironment that enforces cellular homeostasis (Mintz and Illmensee, 1975; Soto and Sonnenschein, 2011; Xu et al., 2009; Bissell and Hines, 2011; Dolberg and Bissell, 1984; Petersen et al., 1992; Wong et al., 1992; Anderson et al., 2006; Wall et al., 2005). By contrast, the emergence of a desmoplastic (activated) stroma, encompassing fibrotic-like modifications of local and recruited fibroblasts based on tumor interactions with the local microenvironment, has been proposed to play a major role in the development and progression of solid tumors such as pancreatic ductal adenocarcinoma (PDAC) and others (Bijlsma and van Laarhoven, 2015;
Tumors are not entirely made out of cancerous cells. They contain many other components – referred to as tumor stroma – that may either encourage or hinder the tumor’s growth. Tumor stroma includes non-cancerous cells and a framework of fibrous sugary proteins, called the extracellular matrix, which surround and signal to cells while providing physical support.

In the most common and aggressive form of pancreatic cancer, the stroma often makes up the majority of the tumor’s mass. Sometimes the stroma of these pancreatic tumors can protect the cancer cells from anti-cancer drugs. Researchers have therefore been interested in finding out exactly which aspects of the tumor stroma shield and support cancer cells, and which impede their growth and progression. Answering these questions could make it possible to develop new drugs that will change a tumor-supporting stroma into one that hinders the tumor’s growth and spread.

The most abundant cells in the stroma of pancreatic tumors are called cancer-associated fibroblasts. Healthy specialized fibroblasts – known as pancreatic stellate cells – help to build and maintain the ‘normal’ extracellular matrix and so these cells normally restrict a tumor’s development. However, cancer cells can adapt healthy fibroblasts into cancer-associated fibroblasts, which produce an altered extracellular matrix that could allow the tumor to grow.

Franco-Barraza et al. have now compared healthy and cancer-associated fibroblasts from patients’ pancreatic tumors. One of the main differences between these two cell types was the location of the activated form of a molecule called $\alpha_5\beta_1$-integrin. Healthy fibroblasts, in a normal extracellular matrix, have active $\alpha_5\beta_1$-integrin on the surface of the cell. However, a number of tumor-promoting signals, including some from the altered extracellular matrix, could force the active $\alpha_5\beta_1$-integrins to relocate inside the fibroblasts instead. In further experiments, where the activated integrin was retained at the cell surface, the fibroblasts were able to resist the influence of the cancer-associated extracellular matrix. Then again, if the active $\alpha_5\beta_1$-integrins were directed inside the cells, healthy cells turned into cancer-associated fibroblasts.

With this information in hand, Franco-Barraza et al. examined tumor samples from over a hundred pancreatic cancer patients using a new microscopy-based technique that distinguishes cancer cells from stroma cells. The analysis confirmed the pattern observed in the laboratory: those patients who appeared to produce more normal extracellular matrix and have active $\alpha_5\beta_1$-integrin localized mostly to the surface of the cells survived longer without the cancer returning than those patients who lacked these stroma traits. Samples from patients with kidney cancer also showed similar results and, as before, an altered extracellular matrix was linked to a worse outcome of the disease.

Together these findings suggest that if future studies uncover ways to relocate or maintain active $\alpha_5\beta_1$-integrin to the cell surface of fibroblasts they could lead to new treatments to restrict the growth of tumors in cancer patients.

DOI: 10.7554/eLife.20600.002

Many studies suggest that a fibrotic reaction, such as that seen in pancreatitis, drives a pro-tumorigenic wound-healing response that often precedes tumor development (Whitcomb and Pogue-Geile, 2002; Binkley et al., 2004). Tumor fibrosis, also known as desmoplasia, has been reported to promote tumorigenesis, providing chemoresistance and shielding tumors from therapeutic agents (Olive et al., 2009; Ireland et al., 2016; Laklai et al., 2016; Koay et al., 2014). A mechanism of ‘stromal reciprocation’, involving mutual signaling between tumor and neighboring cancer-associated fibroblasts (CAFs) that promotes tumor growth, has been demonstrated for PDAC (Tape et al., 2016). On the basis of these findings, several studies have attempted complete ablation of desmoplastic stroma as a therapeutic approach to limit tumor growth, but paradoxically, this resulted in the evolution of existing tumors to a more aggressive state, and accelerated rates of tumorigenesis (Ozdemir et al., 2014; Rhim et al., 2014). By contrast, the idea of chronically ‘normalizing’ activated stroma by reprogramming desmoplasia from a tumor-promoting to a tumor-restrictive state has been suggested to bear greater therapeutic promise (Bijlsma and van Laarhoven, 2015; Sherman et al., 2014; Klemm and Joyce, 2015; Stromnes et al., 2014; Froeling et al., 2011), and...
the identification of a clinically applicable means to revert desmoplastic stroma is of considerable interest (Stromnes et al., 2014; Froeling et al., 2011; Alexander and Cukierman, 2016).

Activation of local fibroblastic pancreatic stellate cells and recruited naïve fibroblastic cells during desmoplasia involves their transforming growth factor-beta (TGFβ)-dependent conversion to a myofibroblastic (activated) phenotype (Desmoulière et al., 1993; Meng et al., 2016; Principe et al., 2016; Xu et al., 2016). This phenotype is characterized by the induction of stress fibers and the elevated expression of alpha-smooth muscle actin (αSMA), palladin and other actin-binding proteins, and by the production of an aligned and organized (anisotropic) ECM, with parallel fibers that are rich in discrete fibronectin splice variants (e.g., ED-A) and in type I collagen (Mishra et al., 2007; Serini et al., 1998; Hinz, 2016; Rönty et al., 2008; Goetz et al., 2011). Despite the strong effect of TGFβ on fibroblast activation and ECM remodeling during epithelial cancer-associated desmoplasia, knowledge of the mechanisms and downstream consequences of this activation remain limited (Hesler et al., 2016; Oshima et al., 2015). In previous studies, we demonstrated that culturing naïve fibroblasts within CAF-secreted D-ECM is sufficient to induce myofibroblastic conversion (Amatangelo et al., 2005). Compatible with this dynamic ECM-dependent reprogramming, specific cell-matrix receptors, such as integrins αβ5 and αβ1, have been identified as regulators of myofibroblastic αSMA (Asano et al., 2006; Lygoe et al., 2004) and as participants in the maturation of specific types of cell-matrix adhesions that support anisotropic fiber formation (Dugina et al., 2001).

In the present work, we first asked whether D-ECM production and the ability of D-ECM to induce myofibroblastic activation can be decoupled and independently regulated. Using a patient-derived human pancreatic model (Lee et al., 2011) as main focus, with supporting data from human renal cancer (Gupta et al., 2011) and additional stromal (Amatangelo et al., 2005) models, we found that although TGFβ is needed for production of D-ECM, it is dispensable for subsequent D-ECM-induction of myofibroblastic activation of naïve fibroblasts. We also found that D-ECM controls αβ5-integrin signaling, which prompts the accumulation of activated, but FAK-independent, αβ1-integrin pools in specific intracellular vesicles. This D-ECM control of αβ5-integrin signaling prevents the enrichment of active αβ1-integrin at the plasma membrane (PM), where αβ1 activity opposes myofibroblastic activation. Using a novel integrative approach combining multi-colored immunofluorescence and a new quantitative algorithm, we first validated our in vitro findings and then applied this process to annotated clinical samples. This defined two readily distinguishable desmoplastic phenotypes that were correlated with markedly distinct clinical outcomes. These phenotypes are based on differences in the stromal localization and levels of either activated SMAD2/3 (indicative of TGFβ signaling) or active αβ1-integrin and FAK. These signatures help clarify the controversial role of desmoplasia in the progression of cancer. Further, insofar as reversion of D-ECM has been suggested have the potential to confer significant clinical benefit (Stromnes et al., 2014; Whatcott et al., 2015; Neuzillet et al., 2015), these data suggest potential therapies to stabilize patient-protective or to revert patient-detrimental stroma.

**Results**

**TGFβ is necessary for CAF production of functional anisotropic D-ECM**

Fibroblasts were isolated from seven PDAC surgical specimens obtained from five different individuals (with four specimens reflecting two matched tumor-normal pairs, one tumor specimen lacking a matched normal control, and two specimens pathologically designated as non-tumor/normal). These fibroblasts were characterized as naïve pancreatic stellate cells or PDAC-associated desmoplastic CAFs on the basis of assessments of the mRNA and protein expression of the myofibroblastic markers palladin and αSMA (Figure 1A–B). All specimens were used in parallel for subsequent analyses. In primary culture, these fibroblasts produced characteristic ECM (Franco-Barraza et al., 2016). Desmoplastic CAFs produced anisotropic D-ECM with multi-layered myofibroblastic spindled nuclei and increased levels of stress fiber-localized αSMA reminiscent of myofibroblastic cells in vivo (Goetz et al., 2011; Provenzano et al., 2006; Conklin et al., 2011; Eyden, 2001; Kalluri and Zeisberg, 2006), whereas fibroblasts derived from normal specimens did not (Figure 1C). Quantification of ECM fiber alignment provided a robust measure of tumor-dependent fibroblast activation. We used an arbitrary quantitative threshold of at least 55% of fibers oriented at a spread of 15° from the
Figure 1. Characterization of human fibroblastic cells isolated from PDAC surgical samples. Fibroblastic cells were isolated from normal or tumoral surgical samples from PDAC patients. (A) Representative indirect immunofluorescent assessments of vimentin-positive and pan-cytokeratin-negative fibroblasts, isolated from PDAC surgical specimens. Harvested cells were probed for desmoplastic markers αSMA and palladin, while the pancreatic cancer cell line, Panc1, was used as an epithelial-to-mesenchymal transduced (EMT) control that is known to express both epithelial and mesenchymal markers. Assorted markers are shown in white while counterstained Hoechst-identified nuclei are shown in yellow. (B) The bar chart shows normal vs. desmoplastic mRNAs levels, corresponding to αSMA and palladin obtained by RT-qPCR from the indicated 3D-cultures following ECM production (obtained by confluent culturing of fibroblasts in the presence of ascorbic acid for a period lasting 8 days [Franco-Barraza et al., 2016]) (**p=0.0286). (C) Representative images of normal vs. desmoplastic phenotypes after 3D ECM production; comparison of low vs. high αSMA levels (white), heterogeneous/round vs. elongated/spindled nuclei (yellow) and disorganized/isotropic vs. parallel aligned/anisotropic ECMs (magenta) are evident in the representative images. Note that the examples shown corresponds to the matching pair of (naïve vs. desmoplastic) fibroblastic cells that were harvested from surgical samples corresponding to patient #1 and that this pair of cells was used for all examples provided in figures below, unless otherwise stated.

DOI: 10.7554/eLife.20600.003

The following figure supplements are available for figure 1:

Figure supplement 1. CAFs produce anisotropic D-ECMs.
DOI: 10.7554/eLife.20600.004

Figure supplement 2. TGFβ inhibition disrupts anisotropy of D-ECM devoid of preventing CAF matrix fibrillogenesis.
DOI: 10.7554/eLife.20600.005

Figure supplement 3. TGFβ inhibition disrupts N-ECM production by naïve fibroblastic stellate cells.
DOI: 10.7554/eLife.20600.006
mode angle as indicative of D-ECMs that had been produced by activated CAFs (Figure 1—figure supplement 1).

To first test if autocrine TGFβ signaling is essential for CAF production of TGFβ that then contributes to the formation of anisotropic D-ECM, we used an ELISA-based approach to measure levels of TGFβ present in D-ECM in comparison to levels found in normal ECM (N-ECM), or in ECM produced by CAFs treated with SB-431542, a small-molecule inhibitor of the TGFβ1 receptor. Levels of TGFβ in D-ECM were ~2 fold higher than in N-ECM or D-ECM produced in the presence of SB-431542 (D +TGFβ in Figure 1—figure supplement 2). Importantly, following SB-431542 treatment, CAFs produced isotropic ECMs that were phenotypically indistinguishable from intact N-ECMs (Figure 1—figure supplement 2B–D). This result differed from that produced by the treatment of control naïve pancreatic stellate cells with SB-431542, which produced interrupted TGFβ signaling that caused complete loss of fibrillogenesis, resulting in the absence of matrix production (Figure 1—figure supplement 3). Together, these results suggested that the increased TGFβ observed in D-ECM was critical for CAF production of anisotropic matrices.

Stripping matrix-producing cells from their secreted ECMs produces a residual 'extracted' matrix into which new fibroblasts (e.g., naïve fibroblastic stellate cells) or cancer cells can be seeded (Franco-Barraza et al., 2016). Using primary human naïve fibroblastic cells, we have previously shown that the residual three-dimensional (3D) D-ECM produced by CAFs is sufficient to induce a myofibroblastic phenotype (Amatangelo et al., 2005). Applying this analysis to pancreatic extracted matrices, we found that D-ECM produced by CAFs in the presence of TGFβ blockade was similar to N-ECM in being incapable of inducing de novo myofibroblastic activation (as reflected by increased αSMA stress fiber localization and protein levels) in naïve fibroblastic stellate cells. By contrast, untreated and control treated D-ECM effectively induced such activation (Figure 2, Table 1). Similar results were obtained using D-ECM and naïve fibroblastic stellate cells for all five PDAC patients (Figure 2—figure supplement 1, and Table 2), suggesting that myofibroblastic activation is a general phenomenon during interactions between naïve pancreatic stellate cells and CAF-produced PDAC-associated D-ECMs. A post-translational effect was implied by the fact that αSMA mRNA levels were comparable in naïve fibroblastic stellate cells cultured in N- vs D-ECM (Figure 2—figure supplement 2A) and because use of cycloheximide to inhibit protein translation did not alter αSMA expression levels (Figure 2—figure supplement 2B), whereas αSMA localization differed (Figure 2). We also asked whether autocrine TGFβ signaling within naïve stellate cells is necessary for their myofibroblastic activation by D-ECM (Figure 2—figure supplement 3 and Table 3). Growth of these cells in the presence of SB-431542 did not block D-ECM-induced αSMA expression or localization to stress fibers.

Together, these results suggested that TGFβ inhibition during D-ECM production reduces the ability of CAFs to produce ECM that can induce myofibroblastic activation, but that once D-ECM has been deposited by CAFs, TGFβ retained within the D-ECM is subsequently dispensable for D-ECM-induced myofibroblastic activation of naïve stellate cells.

D-ECM controls α5β5 signaling to regulate active α5β1-integrin during naïve-to-myofibroblastic activation

Integrins α5β5 and α5β1 have been reported to participate in myofibroblastic activation (Asano et al., 2006; Lygoe et al., 2004; Dugina et al., 2001). We first established that both of these integrin heterodimers were highly abundant, compared to other β-integrins, on the PMs of human naïve pancreatic stellate cells and of PDAC-associated CAFs (Figure 3A). To determine whether either or both of these heterodimers is essential for D-ECM induction of myofibroblastic conversion, naïve fibroblastic stellate cells were plated overnight on N-ECM or D-ECM in the presence of integrin-inhibitory or negative control antibodies. ALULA, a highly specific α5β5-integrin-blocking antibody (Su et al., 2007), eliminated the ability of D-ECM to induce αSMA stress fiber localization (and expression) beyond levels induced by N-ECM (Figure 3B–E and Table 4). By contrast, mAb16, which specifically blocks human α5β1-integrin activity (Akiyama et al., 1989), had limited effects on D-ECM induction of αSMA localization (or expression), with naïve cells undergoing robust myofibroblastic conversion (Figure 3B–E and Table 4). Intriguingly, combined application of ALULA and mAb16 eliminated the effects of α5β5-integrin inhibition seen with ALULA alone, with naïve cells undergoing robust myofibroblastic transition similar to that in untreated and IgG controls.
**Figure 2.** TGFβ is necessary for functional CAF-produced D-ECM. Naïve PDAC fibroblasts were cultured overnight within normal (N-ECM) vs. desmoplastic (D-ECM) ECMs that were produced in the presence or absence of TGFβ1-receptor inhibitor (D + TGFβi) or vehicle control (D + DMSO). All samples were subjected to indirect immunofluorescent labeling of αSMA and counterstained with fluorescently labeled phalloidin to detect actin stress fibers (F-actin). (A) Monochromatic images indicating double-labeled staining for αSMA and F-actin. (B) Quantification of the levels of localization of αSMA to actin stress fibers (F-actin) from (A). (C) Pseudo-colored images representing intensity-maps of αSMA levels, with an intensity color bar scale (0–255 intensity tone values) shown to the right. (D) Quantification of αSMA intensity from (C). Untreated D-ECM conditions were included in all experiments summarized in this figure and served as normalization controls (one arbitrary unit; a.u.). Checkmarks indicate conditions that induce myofibroblastic activation phenotypes. X marks indicate conditions that did not induce myofibroblastic activation. All quantifications and p-values can be found in Table 1.

DOI: 10.7554/eLife.20600.010

The following figure supplements are available for figure 2:

**Figure supplement 1.** Primary CAF-produced D-ECMs induce naïve-to-myofibroblastic activation in normal pancreatic stellate cells.

DOI: 10.7554/eLife.20600.011

**Figure supplement 2.** D-ECM imparts αSMA post-translational effects during naïve-to-myofibroblastic activation.

DOI: 10.7554/eLife.20600.012

**Figure supplement 3.** TGFβ activity is dispensable for D-ECM-induced naïve-to-myofibroblastic activation.

DOI: 10.7554/eLife.20600.013
Note that quantitative immunofluorescent obtained values of ECM while experimental conditions included D-ECMs made by CAFs treated with SB-431542 (from patient #1) were used for normalization and assigned an arbitrary unit of 1.00. Assorted, patient #1 derived, ECMs were intact

**Table 1.** αSMA stress fiber localization and expression levels in naïve fibroblasts (stellate cells) cultured overnight within assorted ECMs.

|                | N-ECM | D-ECM | D+TGFβi | D+DMSO |
|----------------|-------|-------|---------|--------|
| **αSMA**       |       |       |         |        |
| Stress fiber localization |
| 25% percentile | 0.17  | 0.82  | 0.32    | 0.85   |
| Median         | 0.58  | 1.00  | 0.55    | 1.02   |
| 75% percentile | 1.07  | 1.12  | 0.87    | 1.40   |
| expression     |
| 25% percentile | 0.05  | 0.41  | 0.52    | 0.48   |
| Median         | 0.27  | 1.00  | 0.73    | 0.89   |
| 75% percentile | 0.78  | 1.50  | 1.14    | 1.19   |

Values obtained from naïve cells (pancreatic stellate cells isolated from patient #1) cultured overnight within intact D-ECMs (made from CAFs isolated from patient #1) were used for normalization and assigned an arbitrary unit of 1.00. Assorted, patient #1 derived, ECMs were intact D-ECM while experimental conditions included D-ECMs made by CAFs treated with SB-431542 (D+TGFβi) or DMSO (D+DMSO) during ECM production. Note that quantitative immunofluorescent obtained values of αSMA and F-actin were used to calculate stress fiber localization and expression of αSMA. P values, listed below, were calculated using the two-sided and two-tailed Mann Whitney test needed for normalized data.

N-ECM vs. D-ECM; p<0.0001 stress fiber localization; p<0.0001 expression
N-ECM vs. D+TGFβi; p=0.8847 stress fiber localization; p=0.0198 expression
N-ECM vs. D+DMSO; p=0.0036 stress fiber localization; p=0.6236 expression
D-ECM vs. D+TGFβi; p<0.0001 stress fiber localization; p=0.1208 expression
D-ECM vs. D+DMSO; p=0.3578 stress fiber localization; p=0.8847 stress fiber localization; p<0.0001 stress fiber localization; p<0.0001 expression

(Figure 3B–E and Table 4). This raised the possibility that inhibition of α5β1 might act downstream of inhibition of α5β3 in receiving D-ECM signals.

To test whether these signaling interactions were specific to human pancreatic cells or also observed in other systems, we used murine skin squamous cell carcinoma associated fibroblasts, which are known to produce myofibroblastic-activating D-ECMs (mD-ECM) (Amatangelo et al., 2005). We cultured naïve murine skin fibroblasts within mD-ECM overnight in the presence of ALULA alone, to inhibit α5β2-integrin, or in combination with BMA5, to inhibit the activity of murine α5β1-integrin specifically (Fehlner-Gardiner et al., 1996). The results of this experiment (Figure 3F) paralleled those seen with pancreatic stellate cells, suggesting a general mechanism.

To explore the observation that α5β2-integrin-induced myofibroblastic activation is dispensable upon loss of α5β1-integrin activity, we directly tested the possibility that α5β2-integrin negatively regulates α5β1-integrin to prevent active α5β1 from blocking D-ECM-induced activation (see model in Figure 3G). For this, we asked whether stabilizing the activity of α5β1-integrin could phenocopy α5β2-integrin inhibition. We found that SNAKA51, an activating antibody that stabilizes the active conformation of α5β1-integrin (Clark et al., 2005), reduced the ability of D-ECM to induce αSMA stress fiber localization (and expression) in naïve stellate cells (Figure 3 and Table 4). As an independent approach to simulate ALULA-dependent inhibition of α5β2-integrin, we used Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-editing to generate a series of naïve stellate cells in which the β2, α5, αv, or β3 (a negative control) integrin subunits were ablated (Figure 3—figure supplements 1 and 2). Cells lacking the β2 subunit had a greatly diminished response to D-ECM, with very limited induction of αSMA stress fiber localization (and expression) (Figure 3—figure supplement 1). By contrast, loss of α5, αv, or β3-integrin profoundly reduced growth of naïve fibroblasts, yielding slow-growing cells that were also unable to respond to D-ECM. The slow growth and poor condition of the additional KO cells suggests pleiotropic roles for these integrin subunits in supporting cell viability, and thus makes it difficult to draw conclusions. Nonetheless, the results do not rule out a role for α5β1-integrin activity, regulated by D-ECM control of α5β2-integrin, that opposes the stimulation of the naïve-to-myofibroblastic transition (Figure 3G).
Next, we asked whether manipulation of integrin activities in CAFs, as opposed to in naïve stellate cells, could influence their ability to produce functional D-ECM. In contrast to results with TGFβ blockade, neither α,β5-integrin inhibition (with ALULA) nor stabilization of active α6β5-integrin (with SNAKA51) altered the anisotropic fiber formation in D-ECM deposited by CAFs (Figure 4-—figure supplement 1). We also analyzed the ECM produced by CRISPR-edited CAFs lacking specific integrin subunits. In contrast to results with integrin inhibition, CAFs lacking β5-integrin or α5-integrin subunits had decreased αSMA expression and localization of αSMA to stress fibers. Loss of β5 expression also affected levels of D-ECM anisotropy, while CAFs lacking α5 failed to produce substantial matrices (matching earlier reports [Pankov et al., 2000; McDonald et al., 1987; Fogerty et al., 1990]) (Figure 4—figure supplement 2). In addition, loss of α5-integrin caused significant reduction in the ability to produce D-ECM, while loss of the negative control, β3, had no effect on this phenotype (Figure 4—figure supplement 3). These results suggested that the ability of CAFs to grow and produce functional D-ECMs was selectively affected by loss of α5, αv and β5 integrin subunits but not by β3 loss.

Together, these data indicated that the requirement for specific integrins in the response of naïve fibroblastic cells to D-ECMs differs from the requirement for integrins during CAF production of anisotropic D-ECMs.
As an additional control to Figure 5—figure supplement 2, we cultured naive cells overnight in the presence of TGFβ1, and again, an efficient rescue of this phenotype was imparted by PF573,228 treatment alone, while PF573,228 blocked acquisition of myofibroblastic traits, similar to the result seen with mD-ECM (Figure 5). Further, naive pancreatic stellate cells treated concomitantly with PF573,228 and the α5β1-integrin-inhibiting mAb16 (Akiyama et al., 1989) underwent a myofibroblastic conversion, re-localizing and upregulating αSMA (Figure 5).

Emphasizing a general mechanism, treatment of naive murine fibroblasts plated in mD-ECM with PF573,228 blocked acquisition of myofibroblastic traits (Figure 5—figure supplement 1). In naive murine fibroblasts, concomitant FAK and α5β1-integrin inhibition with combined PF573,228 and BMA5 significantly increased mD-ECM-induced myofibroblastic conversion when compared with PF573,228 treatment alone, while α5β3-integrin co-inhibition with FAK did not (Figure 5—figure supplement 1). Further, FAK+/− murine naive fibroblastic cells (Ilič et al., 1995) grown in mD-ECM had greatly reduced myofibroblastic activation, which was significantly increased if α5β1 but not α5β3 integrin activation was blocked (Figure 5—figure supplement 2). As an additional control to exclude off-target or indirect effects of drug inhibition or FAK KO background compensation, we asked whether murine fibroblasts engineered to express a dominant negative FAK Kinase-Dead mutant (FAK-KD) (Lim et al., 2010) behaved similarly to those with deleted or inhibited FAK, and whether they also recovered responsiveness to D-ECM following inhibition of α5β1-integrin activity. Immortalized murine fibroblasts overexpressing FAK-KD displayed a lack of myofibroblastic response to mD-ECM compared to the response seen in isogenic hTert immortalized control cells, and again, an efficient rescue of this phenotype was imparted by α5TERT integrin inhibition (Figure 5—figure supplement 3).

FAK often interacts with SRC family kinases to mediate integrin signaling. To further probe the mechanisms, we evaluated the mD-ECM responsiveness of fibroblasts cells that are genetically null for the SRC family kinases SRC, FYN and YES (Klinghoffer et al., 1999). We found that the ablation

**Table 3.** αSMA stress fiber localization and expression levels in naive fibroblasts (stellate cells) cultured overnight in the presence or absence of TGFβ inhibitor within intact D-ECMs.

| αSMA | Stress fiber localization | TGFβ-i | DMSO |
|------|---------------------------|--------|------|
|      | 25% percentile blind      |        |      |
|      | Median                    |        |      |
|      | 75% percentile blind      |        |      |

Values obtained from naive cells cultured overnight within intact D-ECMs were used for normalization (as shown in Table 1) and assigned an arbitrary unit of 1.00. TGFβ-i is the experimental condition in which naive pancreatic stellate cells were cultured overnight in the presence of SB-431542 within intact D-ECM. DMSO treatment corresponds to vehicle control. Note that quantitative immunofluorescent obtained values of αSMA and F-actin were used to calculate stress fiber localization and expression of αSMA.

P values, listed below, were calculated using the two-sided and two-tailed Mann Whitney test needed for normalized data.

| αSMA | Stress fiber localization | TGFβ-i | DMSO |
|------|---------------------------|--------|------|
|      | 25% percentile            | 0.71   | 0.72 |
|      | Median                    | 0.96   | 1.00 |
|      | 75% percentile            | 1.29   | 1.04 |

**FAK-independent α5β1-integrin activity blocks D-ECM-induced naïve-to-myofibroblastic activation**

Although integrins often signal through focal adhesion kinase (FAK), an increasing number of FAK-independent integrin signaling activities have been observed (Cukierman et al., 2001; Wu et al., 2008; Zoppi et al., 2008; Horton et al., 2016). We investigated the role of FAK in D-ECM-induced myofibroblast activation, treating naive fibroblastic stellate cells plated in D-ECM with the small molecule FAK inhibitor PF573,228 (Slack-Davis et al., 2007). FAK inhibition strongly reduced the ability of these cells to acquire myofibroblastic traits, similar to the result seen with α5β1-integrin inhibition (Figure 5).

Further, naive pancreatic stellate cells treated concomitantly with PF573,228 and the α5β1-integrin-inhibiting mAb16 (Akiyama et al., 1989) underwent a myofibroblastic conversion, re-localizing and upregulating αSMA (Figure 5).

Although integrins often signal through focal adhesion kinase (FAK), an increasing number of FAK-independent integrin signaling activities have been observed (Cukierman et al., 2001; Wu et al., 2008; Zoppi et al., 2008; Horton et al., 2016). We investigated the role of FAK in D-ECM-induced myofibroblast activation, treating naive fibroblastic stellate cells plated in D-ECM with the small molecule FAK inhibitor PF573,228 (Slack-Davis et al., 2007). FAK inhibition strongly reduced the ability of these cells to acquire myofibroblastic traits, similar to the result seen with α5β1-integrin inhibition (Figure 5). Further, naive pancreatic stellate cells treated concomitantly with PF573,228 and the α5β1-integrin-inhibiting mAb16 (Akiyama et al., 1989) underwent a myofibroblastic conversion, re-localizing and upregulating αSMA (Figure 5).

Emphasizing a general mechanism, treatment of naive murine fibroblasts plated in mD-ECM with PF573,228 blocked acquisition of myofibroblastic traits (Figure 5—figure supplement 1). In naive murine fibroblasts, concomitant FAK and α5β1-integrin inhibition with combined PF573,228 and BMA5 significantly increased mD-ECM-induced myofibroblastic conversion when compared with PF573,228 treatment alone, while α5β3-integrin co-inhibition with FAK did not (Figure 5—figure supplement 1). Further, FAK+/− murine naive fibroblastic cells (Ilič et al., 1995) grown in mD-ECM had greatly reduced myofibroblastic activation, which was significantly increased if α5β1 but not α5β3 integrin activation was blocked (Figure 5—figure supplement 2). As an additional control to exclude off-target or indirect effects of drug inhibition or FAK KO background compensation, we asked whether murine fibroblasts engineered to express a dominant negative FAK Kinase-Dead mutant (FAK-KD) (Lim et al., 2010) behaved similarly to those with deleted or inhibited FAK, and whether they also recovered responsiveness to D-ECM following inhibition of α5β1-integrin activity. Immortalized murine fibroblasts overexpressing FAK-KD displayed a lack of myofibroblastic response to mD-ECM compared to the response seen in isogenic hTert immortalized control cells, and again, an efficient rescue of this phenotype was imparted by α5TERT integrin inhibition (Figure 5—figure supplement 3).

FAK often interacts with SRC family kinases to mediate integrin signaling. To further probe the mechanisms, we evaluated the mD-ECM responsiveness of fibroblasts cells that are genetically null for the SRC family kinases SRC, FYN and YES (Klinghoffer et al., 1999). We found that the ablation
Figure 3. Integrin αβ5 regulates α5β1 activity thereby maintaining D-ECM-induced naïve-to-myofibroblastic activation. (A) An integrin-dependent cell adhesion array test was used to assess the PM expression of integrin heterodimers in primary fibroblasts isolated from normal (white bars) vs. matched tumor tissue (desmoplastic; dark bars). Note that no differences were apparent between the two cell types with regards to levels of αvβ5 and α5β1 integrins. (B) Naïve human pancreatic fibroblastic stellate cells were re-plated onto D-ECMs overnight in the presence of functional blocking anti-αvβ5-
integron (ALULA [Su et al., 2007]; αβ1-i), functional blocking anti-αβ1-integrin (mAb16 [Akiyama et al., 1989]; αβ1-act), or non-immunized isotypic antibodies (IgG). Representative monochromatic images of αSMA- and F-actin stained fibroblasts are shown. (C) Quantification of the experiment performed in (B). (D) Pseudocolored images depicting the intensity of αSMA expression including a color bar scale (0–255 intensity tone values). (E) Quantification of (D). Note that corresponding quantifications and p-values, for results shown in (B–E) are summarized in Table 4. (F) Naïve murine skin fibroblasts were replated onto murine D-ECMs (mD-ECM) produced by murine skin squamous cell carcinoma associated CAFs (Amatangelo et al., 2005), and subjected to αβ1-integrin and αβ1-integrin inhibitors alone (ALULA. αβ1-i [Su et al., 2007] and BMAS: αβ1-i) or in combination (β5+α5-i). The effects on myofibroblastic activation were measured for αSMA as in (B). The red asterisk illustrates the area outlined in red in the magnified insert for the intact (untreated) control. The same magnification is shown for the experimental conditions in the additional panels. As a method of quantifying the percentage of cells showing myofibroblastic features, the percentage of cells that have a stress fiber localized (αSMA) phenotype is shown (**p<0.0001). Note that inhibition of αβ1-integrin effectively reconstituted the D-ECM-induced phenotype that was lost by inhibition of αβ5-integrin, just as seen above for the human PDAC system. Checkmarks identify conditions that resulted in myofibroblastic activation, while Xs identify conditions that did not result in myofibroblastic activation. (G) Model of D-ECM-induced activation of naïve fibroblasts, dependent on the activity of integrins αβ5 and αβ1. Inhibition of αβ5-integrin results in release of active αβ5-integrin, leading to blockade of D-ECM-induced myofibroblastic activation (1st arrow, red X). The activity of αβ1-integrin is no longer needed in the absence of αβ1-integrin activity, suggesting that αβ1-integrin activity in not necessary for fibroblasts to undergo D-ECM-induced myofibroblastic activation (2nd arrow, green checkmark). Double inhibition of αβ1-integrin and αβ1-integrin results in D-ECM myofibroblastic activation, which proposes that inhibition of αβ1-integrin can overcome or rescue the effects seen under αβ1-integrin inhibition (3rd arrow, green checkmark). Stabilization of αβ1-integrin in its active conformation overcomes the inhibitory/regulatory effects imparted by αβ1-integrin, resulting in ineffective D-ECM-induced myofibroblastic activation (4th arrow, red X). Overall, the model suggests that D-ECM induces αβ1-integrin activity, which in turn results in the regulation of active αβ1-integrin, allowing D-ECM-induced myofibroblastic activation (large arrow to the right, green checkmark).

DOI: 10.7554/eLife.20600.015

The following figure supplements are available for figure 3:

Figure supplement 1. Naïve β5-integrin KO fibroblasts display stunted D-ECM-induced myofibroblastic activation.
DOI: 10.7554/elife.20600.016

Figure supplement 2. Expression of α5, α7- and β1-integrins in naïve fibroblastic stellate cells is necessary for D-ECM-induced myofibroblastic activation.
DOI: 10.7554/elife.20600.017

---

**Table 4. αSMA stress fiber localization and expression levels in naïve fibroblasts (stellate cells) cultured overnight within D-ECMs in the presence of integrin functional antibodies.**

| αβ5-i | αβ1-i | β5+α5-i | αβ1-act | IgG |
|-------|-------|---------|--------|-----|
| **αSMA Stress fiber localization** | | | | |
| 25% percentile | 0.14 | 0.51 | 0.83 | 0.41 | 0.92 |
| Median | 0.54 | 0.77 | 1.11 | 0.56 | 1.00 |
| 75% percentile | 0.71 | 1.20 | 1.55 | 0.98 | 1.00 |
| **expression** | | | | |
| 25% percentile | 0.11 | 0.31 | 0.44 | 0.08 | 0.31 |
| Median | 0.29 | 0.71 | 0.90 | 0.32 | 1.25 |
| 75% percentile | 0.70 | 1.27 | 2.09 | 0.96 | 1.95 |

Values obtained from naïve cells cultured overnight within intact D-ECMs treated with ALULA (αβ5-i), mAb16 (αβ1-i), ALULA plus mAb16 (β5+α5-i), SNAKA (αβ1-act) or control pre-immune antibody (IgG). Values obtained in untreated D-ECMs (from Table 1) were used for normalization and assigned an arbitrary unit of 1.00. Note that the quantitative values of αSMA and F-actin obtained by immunofluorescence were used to calculate stress fiber localization and expression of αSMA.

P values, listed below, were calculated using the two-sided and two-tailed Mann Whitney test needed for normalized data:

αβ5-i vs. IgG: p=0.0001 stress fiber localization; p=0.0002 expression
αβ1-i vs. IgG: p=0.1311 stress fiber localization; p=0.1229 expression
β5+α5-i vs. IgG: p=0.0333 stress fiber localization; p=0.9171 expression
αβ1-act vs. IgG: p=0.0047 stress fiber localization; p=0.0020 expression

DOI: 10.7554/eLife.20600.014

---

Franco-Barraza et al. eLife 2017;6:e20600. DOI: 10.7554/eLife.20600
Figure 4. Transient αvβ5-integrin inhibition or α5β1-integrin stabilization failed to alter CAF production of anisotropic D-ECM. (A) Representative indirect immunofluorescent images of 3D D-ECM producing CAFs in the presence of functional blocking anti-αvβ5-integrin (ALULA [Su et al., 2007]; D + αvβ5-i), active conformation stabilizing anti-α5β1-integrin (SNAKA51 [Clark et al., 2005]; D + α5β1-act.) or non-immunized isotypic antibodies (D + IgG). Spinning disk confocal monochromatic images, obtained following indirect immunofluorescence, show nuclei (Hoechst; yellow), αSMA (white) and ECM (fibronectin; magenta). (B) The corresponding ECM fiber angle distributions, determined by Image-J’s ‘Orientation J’ plugin, were normalized using hue values for a cyan mode angle visualization as shown in the bar on the right. (C) Corresponding curves depicting experimental-repetition-averaged variations of angle distributions normalized to 0° modes and summarizing the results. Dotted lines correspond to 15° fiber angle spreads. (D) Plotted data depicting summarized percentages of fibers distributed at 15° angles from the mode for each experimental condition. The dotted line denotes 55% alignment. Note how none of the treatments seem to have altered the myofibroblastic features of CAFs or their capability to produce anisotropic D-ECMs.

DOI: 10.7554/eLife.20600.018

The following figure supplements are available for figure 4:

Figure supplement 1. D-ECMs produced by CAFs under transient αvβ5-integrin inhibition or stabilization of α5β1-integrin activity are functionally intact.

DOI: 10.7554/eLife.20600.019

Figure supplement 2. Loss of β5-integrin expression in CAFs impairs D-ECM anisotropy, while expression of α5-integrin is imperative for effective ECM fibrillogenesis.

DOI: 10.7554/eLife.20600.020

Figure supplement 3. KO of αv-integrin, but not β3-integrin, disrupts CAF myofibroblastic features and D-ECM production.

DOI: 10.7554/eLife.20600.021
Figure 5. FAK-independent α5β1-integrin activity negatively regulates PDAC D-ECM-induced naïve-to-myofibroblastic activation. Naïve fibroblasts were re-plated onto D-ECMs and challenged with either control conditions (DMSO + IgG), small molecule FAK inhibitor PF573,228 (Slack-Davis et al., 2007) (FAK-i) alone or FAK inhibitor in combination with α5β1-integrin inhibitor (FAK-i + α5-i, mAb16 (Akiyama et al., 1989)), and activation of fibroblasts was tested. (A) Representative monochromatic images of immunofluorescently labeled αSMA and actin stress fibers (F-actin). Colored asterisks in (A) represent areas that are magnified in the corresponding panels to the right. (B) Quantification of αSMA at actin stress fibers (F-actin) from the experiment in (A) and normalized to DMSO + IgG control (one arbitrary unit; a.u.) (**p<0.0001). (C) Pseudocolored images represent intensity maps of αSMA, with an intensity color bar scale (0–255 intensity tone values) shown to the right. (D) Quantification of αSMA intensity from (C) (**p=0.0001). Note that the D-ECM-induced phenotype that was lost under FAK inhibition was rescued under α5β1-integrin co-inhibition (just as for the two integrin co-inhibitions shown in Figure 3).

DOI: 10.7554/eLife.20600.022

The following figure supplements are available for figure 5:

Figure supplement 1. FAK-independent α5β1-integrin activity negatively regulates mD-ECM-induced murine naïve-to-myofibroblastic activation.

Figure 5 continued on next page
of SRC family kinases also negated the ability of fibroblasts to respond to mD-ECM. Interestingly, in this context, inhibition of $\alpha_5\beta_1$-integrin did not restore the mD-ECM-induced myofibroblastic phenotype, indicating non-equivalent functions of FAK and SRC (Figure 5—figure supplement 4). Last, we explored the relationship between FAK and $\alpha_5$-integrin expression (as opposed to integrin activity). The ability of the FAK inhibitor to block D-ECM-induced myofibroblastic transition depended on an intact $\alpha_5\beta_1$ heterodimer, as PFS73,228 did not rescue the mD-ECM-induced process that was disrupted in $\alpha_5$-KO naïve stellate cells (Figure 5—figure supplement 5).

Together, these results suggested that FAK is essential for D-ECM-induced myofibroblast activation, but dispensable for the $\alpha_5\beta_1$-integrin inhibition of this process. The data further indicate that genetic ablation of $\alpha_5\beta_1$-integrin does not recapitulate the result of inhibition of integrin activity in D-ECM responsiveness, perhaps due to additional functional requirements for this integrin in supporting fundamental cell growth.

D-ECM regulates length of 3D-adhesion structures concomitant with $\alpha_5\beta_5$-integrin-dependent redistribution of active $\alpha_5\beta_1$-integrin to endosomal vesicles

In vivo, fibroblasts engage N-ECM through 3D matrix adhesion structures (3D-adhesions) that mediate matrix-dependent homeostasis (Cukierman et al., 2001). 3D-adhesions are elongated adhesion plaques that depend on $\alpha_5\beta_1$-integrin activity for their formation and are characterized by encompassing active $\alpha_5\beta_1$-integrin concomitant with constitutive, albeit low, levels of auto-phosphorylated, activated FAK (pFAK-Y397) (Cukierman et al., 2001). We tested the idea that D-ECM might alter structure, protein composition, or signaling at 3D-adhesions. Naïve stellate cells cultured within D-ECM typically increased the length of 3D-adhesions by ~14% compared to adhesions formed in N-ECM (Figure 6). While inhibition of $\alpha_5\beta_1$-integrin with mAb16 was previously shown to cause 3D-adhesion loss (Cukierman et al., 2001), stabilization of $\alpha_5\beta_1$-integrin activity using SNAKA51 eliminated the ability of D-ECM to induce 3D-adhesion lengthening. However, $\alpha_5\beta_5$-integrin inhibition with ALULA did not (Figure 6). These results separate the requirements for D-ECM-induced $\alpha_5\beta_5$-integrin regulation of $\alpha$SMA (Figure 3) from the lack of requirement for $\alpha_5\beta_5$-integrin for adhesion reorganization in naïve fibroblastic cells.

Next, we developed a semi-quantitative indirect immunofluorescence analytic method (based on SMIA-CUKIE software; see Methods) to evaluate the total intensity of active $\alpha_5\beta_1$-integrin, versus its relative intensity, and area distributions related to 3D-adhesion sites. Plating of naïve stellate cells in D-ECM induced a 4-fold increase in active $\alpha_5\beta_1$-integrin levels compared to plating in N-ECM (Figure 6—figure supplement 1), but surprisingly, this did not reflect an increase in $\alpha_5\beta_1$ localized to 3D adhesions (Figure 6—figure supplement 2A) but rather a concentration (~2 fold) in membrane-proximal regions areas lacking adhesions. To test the idea that D-ECM might affect the recruitment or activation of FAK in 3D adhesions, potentially through control of $\alpha_5\beta_1$-integrin activation or localization, we also examined the localization of activated FAK (pFAK-Y397) to 3D adhesions. Results normalized to levels obtained in D-ECMs (a.u. = 1.0) indicated that D-ECM induced ~2 fold more pFAK-Y397 than N-ECM, and that this activated FAK was localized at 3D-adhesions (Figure 6—figure supplement 2B). By contrast, if fibroblasts are cultured in the presence of the $\alpha_5\beta_1$-integrin inhibitor ALULA, significantly lower levels of pFAK-Y397 at 3D-adhesions and active $\alpha_5\beta_1$-integrin away from 3D-adhesions were observed in cells cultured within D-ECM (Figure 6—figure supplement 2B–C). A
Figure 6. D-ECM regulates 3D-adhesion structure length, dependent on αvβ1-integrin activity. (A) Indirect immunofluorescent and spinning disc confocal generated images of 3D-adhesions (identified using mAb11) (Cukierman et al., 2001), formed by naïve fibroblastic cells cultured within N-ECM or D-ECM in the absence (cnt.) or presence of ALULA (Su et al., 2007) for αvβ5-integrin inhibition (αvβ5-i) or SNAKA52 (Clark et al., 2005) to stabilize αvβ1-integrin activity (α5β1 act) or IgG as control. (A) The artificially colored structures represent computer-selected internally threshold objects (ITOs) of 3D-adhesion structures. (B) Quantification of the length of ITO generated objects from (A) (***p=0.0026. ****p<0.0001). Note the significant differences in 3D-adhesion length observed between N-ECM and D-ECM as well as between IgG and SNAKA51 treatments.

DOI: 10.7554/eLife.20600.028

The following figure supplements are available for figure 6:

Figure supplement 1. Naïve fibroblastic cells increase overall levels of active αvβ1-integrin in response to D-ECM.
DOI: 10.7554/eLife.20600.029

Figure supplement 2. D-ECMs induce an increase in pFAK levels at 3D-adhesions and redistribution of increased active αvβ1-integrin to locations away from 3D-adhesions.
DOI: 10.7554/eLife.20600.030

Figure supplement 3. D-ECM-induced increase in active αvβ1-integrin is reversed by inhibition of αvβ5-integrin.
DOI: 10.7554/eLife.20600.031

Figure supplement 4. D-ECM induces intracellular accumulation of active αvβ1-integrin.
DOI: 10.7554/eLife.20600.032

Figure supplement 5. D-ECM-induced increase in intracellular αvβ1-integrin activity is regulated by αvβ5-integrin.
DOI: 10.7554/eLife.20600.033
summary of results regarding the levels and locations of active α5β1-integrin is shown in Figure 6—figure supplement 3.

To better refine the location of α5β1-integrin activation, and taking advantage of the fact that the epitope recognized by SNAKA51 is typically extracellular with PM-localized integrin (Clark et al., 2005), we performed SMIA-CUKIE analysis comparing SNAKA51 levels in permeabilized versus non-permeabilized cells plated on D-ECM versus N-ECM. Non-permeabilized cells had a 5-fold reduction of detectable D-ECM-induced active (SNAKA51-positive) α5β1-integrin relative to permeabilized cells (Figure 6—figure supplement 4), indicating that the activated integrin may be rapidly internalized. As a control and to demonstrate the specificity of the active integrin conformation detection, we demonstrated that D-ECM treatment in the presence of the mAb16 inhibitory antibody eliminated all detectable active α5β1-integrin. In addition, inhibition of α5β1-integrin, by treatment with ALULA, effectively eliminated the intracellular pool while it considerably increased the amounts of surface-exposed active α5β1-integrin induced by growth in D-ECM (Figure 6—figure supplement 5).

Generally similar results were obtained in analysis of pancreatic human naïve stellate cells deficient in discrete integrin subunits. Naïve β5-integrin KO fibroblastic stellate cells plated within D-ECM had 2.7- and 2.5-fold decreases in total α5β1-integrin activity and pFAK-Y397 levels, respectively, when compared to control KO cells (Figure 7). Experiments were also conducted using naïve α5, α4, and β3-integrin KO stellate cells as controls. As expected, no detectable active α5β1-integrin activity was observed in α5-KO, while only modest decreases in the activity of α5β1-integrin was observed in α5 and β3-integrin KO cells grown in intact D-ECM. Interestingly, while a modest pFAK-Y397 downregulation was observed in α5-KO, there were no appreciable changes in pFAK-Y397 in α5-KO cells, whereas a small increase in pFAK-Y397 was induced by D-ECM in β3-integrin KO fibroblastic stellate cells (Figure 7—figure supplement 1). Although results with α5- and β3-integrin KO did not exclude these integrins from any role in response to D-ECM, these experiments indicated that β5-integrin was an effective regulator of both active α5β1-integrin and pFAK-Y397 levels in the response of naïve stellate cells to D-ECM. These results suggest that the observed requirements in naïve fibroblasts for D-ECM-regulated αβ5-integrin induction of αSMA (Figure 3) are concomitant with α5β3-integrin control of redistributions and levels of active α5β1-integrin and pFAK-Y397.

We next examined whether stabilizing α5β1-integrin activity with SNAKA51 altered its D-ECM-regulated intracellular relocation. For this, naïve pancreatic stellate cells were cultured overnight in D-ECM in the presence of Alexa 660 fluorophore pre-labeled SNAKA51 or of Alexa 660 pre-labeled isotype antibody control. Cells were then fixed with or without permeabilization and visualized with additional SNAKA51 pre-labeled with a different fluorophore (Alexa 488). SNAKA51 stabilization of α5β1-integrin activity reduced intracellular, while increasing PM, pools of active α5β1-integrin when compared to a non-specific IgG treatment control (Figure 8A). As an independent approach to confirm this result, double immunogold labeling of 3D-adhesions with mAb11 and active α5β1-integrin with SNAKA51 was analyzed by transmitted electron microscopy of naïve fibroblastic stellate cells cultured within N-ECM, or of fibroblasts cultured in D-ECM while being treated with the α5β2-integrin inhibiting antibody ALULA or a control antibody. D-ECM induced the intracellular enrichment of the active integrin in discrete punctate structures, which probably reflected endosomes that did not include recognizable clathrin-coated pits. Conversely, inhibition of α5β2-integrin reduced the accumulation of active α5β1-integrin intracellular pools, with most signal localized to the PM (Figure 8B). Supporting this mechanism in an independent model, the relocation of active α5β1-integrin from intracellular to PM locations following culture within intact D-ECM was also observed in naïve β5-integrin KO fibroblastic stellate cells that were compared to control naïve fibroblasts (Figure 8—figure supplement 1).

We directly tested whether the observed intracellular increase in active α5β1-integrin corresponded to enrichment in discrete endosomal vesicles using a double labeling indirect immunofluorescence approach in naïve control and β5-integrin KO pancreatic stellate cells plated into D-ECM. We compared the localization of activated α5β1-integrin to that of proteins restricted to the early (EEA1 and Rab5) and late (Rab7 and Rab11) endosomal compartments, as well as that of a multivesicular endosomal marker (the tetraspanin CD81). D-ECM induced the partial localization of active α5β1-integrin to Rab7-, Rab11-, and most clearly, to CD81-positive endosomes in control KO fibroblasts (Figure 9). By contrast, β5-KO naïve fibroblasts did not similarly relocalize active α5β1-integrin to these intracellular locations following plating in D-ECM.
Figure 7. Loss of β5-integrin expression in naïve fibroblasts effectively reduces D-ECM-induced levels of active α5β1-integrin and pFAK-Y397. (A) Pseudocolored images showing the intensities of representative indirect immunofluorescence images indicating active α5β1-integrin (α5β1-act.) or pFAK from control KO (cntrl KO) or β5-integrin KO (β5-KO1) naïve fibroblasts. The fibroblasts were cultured overnight within D-ECMs. Intensity scale bars are 25 μm.
shown to the right. (B and C) Quantification of total active αvβ3-integrin (**p=0.0420) (B) and pFAK-Y397 (**p=0.0246) (C) levels of cells from (A). Note that both activities that were induced by D-ECM in naïve fibroblasts are lost in β3-integrin KO naïve fibroblastic stellate cells.

DOI: 10.7554/eLife.20600.034

The following figure supplement is available for figure 7:

**Figure supplement 1.** Loss of αv- or β3-integrins does not significantly reduce overall levels of active αvβ1-integrin that is induced by D-ECM in naïve fibroblasts.

DOI: 10.7554/eLife.20600.035

The increase in levels of active αvβ1-integrin that is also evident in D-ECM-producing CAFs is αvβ5-integrin independent

We complemented the preceding analysis of naïve pancreatic integrin KO fibroblasts using the SMIA-CUKIE algorithm to evaluate active αvβ5-integrin and pFAK-Y397 levels in 3D ECM-producing CAFs lacking specific integrin subunits. β5-integrin KO CAFs, which have deficiencies in myofibroblastic expression of αvSMα and in the formation of anisotropic D-ECM (see **Figure 4—figure supplement 2**), had no discernible differences in levels of active αvβ1-integrin when compared to control KO CAFs. However, β5-integrin KO CAFs cells had notable downregulation of pFAK-Y397 expression, suggesting a disturbance in overall integrin signaling that resulted from the loss of this cell-matrix receptor (**Figure 10**). In contrast to the concomitant regulation of stress-fiber-localized αvSMα and of the increased active levels of αvβ1-integrin and FAK in naïve fibroblastic cells responding to D-ECM, a specific mechanistic decoupling between myofibroblastic features, such as αvSMα expression and anisotropic D-ECM production, and the regulation of active αvβ1-integrin in CAFs was observed in this analysis of β5-integrin KO CAFs. This interpretation was further supported by comparative analysis of 3D ECM production in CAFs lacking other integrin subunits. Loss of αv-integrin in CAFs, which led to failure to produce 3D ECMs and to low αvSMα expression, did not affect levels of active αvβ1-integrin, whereas loss of the β5-integrin subunit, which is associated with cells competent for induction of myofibroblastic features, significantly lowered active αvβ1-integrin levels (**Figure 10—figure supplement 1**).

The observed differences between the requirement in CAFs for αvβ5 integrin expression during the concomitant regulation of αvSMα levels and anisotropic D-ECM production, versus the dispensable nature of αvβ5 for the maintenance of high active αvβ1-integrin levels in these cells, suggests a functional decoupling between the processes.

Fibroblasts isolated from RCC patients also display D-ECM- and integrin-dependent naïve-to-myofibroblastic activation

To determine whether the relationships between D-ECM, TGFβ and integrins described above pertain to additional human cancers of clinical relevance, we turned to a human renal cell carcinoma (RCC) stroma model (**Gupta et al., 2011; Goetz et al., 2011**). RCC stroma is of particular interest because it encompasses a microenvironment that is highly angiogenic and that physically intercalates with cancer cells (**Lohi et al., 1998**), thus distinguishing it from the desmoplasia seen in PDAC. We first demonstrated that renal (r) fibroblasts include an overrepresentation of αvβ1 and αvβ2 integrins relative to alternative β-integrin heterodimers at the plasma membrane (**Figure 11A**). Naïve r-fibroblasts expressed low levels of αvSMα (**Figure 11B–C**) and produced isotropic rN-ECM when compared to rCAF-derived matrices, which produced anisotropic rD-ECM (**Figure 11—figure supplement 1**). As with PDAC CAFs, treating rCAFs with a TGFβ inhibitor (SB-431542) during ECM production caused cells to produce isotropic matrices (**Figure 11—figure supplement 1**). Overnight plating of naïve r-fibroblasts in rD-ECM induced the formation of myofibroblastic features such as an increase in stress-fiber-localized αvSMα, as compared to cells plated in rN-ECM. Further, the isotropic 3D matrices produced by TGFβR1-inhibited rCAFs failed to induce naïve-to-myofibroblastic activation, whereas TGFβ signaling activity was dispensable in naïve fibroblasts undergoing myofibroblastic activation in response to intact rD-ECM induction.

In addition, as with the pancreatic model, regulation of active αvβ1-integrin by αvβ5-integrin was needed for naïve fibroblasts to undergo rD-ECM-induced myofibroblastic activation (**Figure 11—figure supplement 2** and **Table 5**). Accordingly, treatment of naïve r-fibroblasts seeded within rD-ECM...
Figure 8. D-ECM prompts the internalization or relocation of αβ1-integrin activity in an αβ1-integrin-dependent manner. (A) Representative indirect immunofluorescent images corresponding to overnight ‘chase’ incubations with pre-labeled anti-active-αβ1-integrin antibodies (SNAKA51 [Clark et al., 2005]) or IgG controls (blue, –not shown), followed by de novo detected active αβ1-integrin labeling after fixation (αβ1-act. in green) relative to 3D-adhesion structures (3D-adh. in red) under permeable vs. non-permeable conditions. Note how SNAKA51 treatment but not IgG prompts

Figure 8 continued on next page
in the presence of small molecule FAK inhibitor PF573,228 (Slack-Davis et al., 2007), blocked acquisition of myofibroblastic traits (Figure 11—figure supplement 3). In naïve r-fibroblasts, concomitant

The relocation of integrin activity to the PM while there is practically no change between permeable and non-permeable active α5β1-integrin levels. (B) Transmitted electron microscopy images of double immunogold-labeled 3D-adhesions (~3D-adh. large particles, [Cukierman et al., 2001]) vs. active α5β1-integrin (~α5β1-act. small particles, [Clark et al., 2005]), detected in naïve cells cultured within N-ECM vs. D-ECM in the presence or absence of α5β1-integrin blockage using ALULA (Su et al., 2007) (α5β5-i). Both reduction and relocation of active α5β1-integrin pools are observed. Arrowheads point at random immunogold particles as examples, while the closed arrow indicates the location of a clathrin-coated vesicle.

DOI: 10.7554/eLife.20600.036

The following figure supplement is available for figure 8:

**Figure supplement 1.** KO of β5-integrin in naïve fibroblasts results in a redistribution of D-ECM-induced active α5β1-integrin from intracellular pools back to the plasma membrane.

DOI: 10.7554/eLife.20600.037

in the presence of small molecule FAK inhibitor PF573,228 (Slack-Davis et al., 2007), blocked acquisition of myofibroblastic traits (Figure 11—figure supplement 3). In naïve r-fibroblasts, concomitant

**Figure 8 continued**

**Figure 9.** Loss of β5-integrin expression in naïve fibroblasts effectively reduces D-ECM-induced relocation of active α5β1-integrin to late and multivesicular endosomes. Control KO (cntrl-KO) or β5-integrin knock-out (β5-KO1) naïve fibroblastic stellate cells were cultured overnight in desmoplastic-ECMs (D-ECM), and were subjected to indirect immunofluorescence using SNAKA51 to detect active α5β1-integrin (α5β1-act in green) in combination with one of the following endosomal markers shown in red: anti-EEA-1 (for early endosome), anti-Rab5 (for clathrin-mediated endocytosis early endosome), anti-Rab7 (late endosome to be degraded, recycled or rerouted), anti-Rab11 (late endosome to be recycled), or anti-CD81 (multivesicular endosomes). Top panels: confocal images were captured for each double-stained condition to identify the localization of active α5β1-integrin in relation to the assorted types of endosomes shown in red. Yellow arrowheads point to assorted endosomes and are identically placed in the slightly zoomed monochromatic inserts shown below, which allow better appreciation of the relative locations of the markers vs. those of active α5β1-integrin. Note that the partial co-localization of active α5β1-integrin with Rab7, Rab11 and especially with CD81 is lost in the naïve β5-KO compared to control KO naïve fibroblasts in response to D-ECM.

DOI: 10.7554/eLife.20600.038
Figure 10. Loss of \( \beta_5 \)-integrin in D-ECM-producing CAFs fails to significantly reduce overall levels of active \( \alpha_5 \beta_1 \)-integrin. Representative indirect immunofluorescence images showing active \( \alpha_5 \beta_1 \)-integrin (with SNAKA51 [Clark et al., 2005] \( \alpha_5 \beta_1 \)-act.) or pFAK in control KO (cntrl-KO) or \( \beta_5 \)-integrin KO (\( \beta_5 \)-KO1) CAFs at the completion of the 3D matrix production process (see Materials and methods). (B-C) Graphs depicting levels of active \( \alpha_5 \beta_1 \).

Figure 10 continued on next page
integrin (B) or pFAK (C, **p = 0.0465) in control and β3-integrin KO CAFs from (A). Note that active αβ1-integrin levels in CAFs were not significantly changed in response to β3-integrin loss.

DOI: 10.7554/eLife.20600.039

The following figure supplement is available for figure 10:

**Figure 11—figure supplement 3.** Loss of β3- but not of α5-integrin subunits in D-ECM-producing CAFs alters levels of active αβ1-integrin.

DOI: 10.7554/eLife.20600.040

FAK and αβ1-integrin inhibition with combined PF573,228 and mAb16 significantly increased rD-ECM-induced myofibroblastic activation compared to PF573,228 treatment alone. Again, effects similar to those observed in the PDAC system were seen: αβ1-integrin co-inhibition with FAK failed to rescue rD-ECM naïve-to-myofibroblastic conversion (Figure 11—figure supplement 3). Also, pFAK-Y397 levels measured in 3D-adhesions of naïve r-fibroblasts induced by rD-ECM were effectively reduced in the presence of αβ1-integrin inhibitor (ALULA [Su et al., 2007]), rendering pFAK-Y397 levels similar to N-ECM levels (Figure 11—figure supplement 4). Culturing naïve r-fibroblasts in rD-ECM triggered lengthening of 3D-adhesion structures compared to those in rN-ECM, and this was effectively prevented by stabilization of αβ1-integrin activity using SNAKA51 (Clark et al., 2005) (Figure 11—figure supplement 5). Last, plating naïve r-fibroblasts in rD-ECM increased levels of active α5β1-integrin that was localized away from 3D-adhesion structures compared to those in rN-ECM. These levels were regulated by αβ1-integrin, as treatment with ALULA restricted the enrichment of αβ1-integrin activity in areas lacking adhesions (Figure 11—figure supplement 6).

Together, these results imply that the mechanisms identified for PDAC D-ECM production and activity were also relevant in RCC-associated fibroblastic stroma.

**In vivo stromal activity and distribution of SMAD2/3, αβ1-integrin, and FAK predict patient survival and neoplastic recurrence**

Reciprocal signaling between tumor and stromal cells occurs in vivo (Tape et al., 2016). Such bidirectional signaling is not simulated in the in vitro stroma 3D model used for the analysis described above. To extend our findings, we assessed whether the results we established in vitro were reflected in vivo in the original surgical samples used to harvest fibroblasts. We investigated whether the integrin redistribution phenotype that was commonly observed in both naïve fibroblasts in response to D-ECM and CAFs during D-ECM production in vitro, was also evident in the in vivo tumor-associated stroma. First, optimizing conditions in vitro, we used a simultaneous multi-channel immunofluorescence (SMI) approach, coupled with SMIA-CUKIE, to perform quantitative parallel analysis of seven relevant biomarkers in CAFs or control normal pancreatic stellate cells at the endpoint of production of D-ECM or N-ECM, respectively. These included a master mix (see Materials and methods) of epithelial and tumor cell markers (cyan; note, absent from in vitro specimens), the stromal marker vimentin (magenta), a nucleus-detecting DNA intercalating agent (Draq5, yellow), a 3D-adhesion marker (mAb11 [Cukierman et al., 2001], red) and SNAKA51 (Clark et al., 2005) to detect levels and localizations of active αβ1-integrin (green), anti-pFAK-Y397 (orange) and anti-pSMAD2/3 (indicative of TGFβ pathway activation [Tsukazaki et al., 1998]; blue).

This method reiterated our observation that during D-ECM production in vitro, CAFs maintain high levels of active αβ1-integrin, with much of the active pool not localized to 3D-adhesions, as well as high levels of pFAK-Y397 that are localized at 3D-adhesions. TGFβ activation also increased during the production of D-ECM, represented by augmented total and nuclear pSMAD2/3 levels, when compared to naïve/normal cultures in which active αβ1-integrin mostly localizes at 3D-adhesion sites during N-ECM matrix production (Figure 12). We also conducted a parallel experiment using a classic indirect immunofluorescence approach to include a two-by-two marker comparison between active αβ1-integrin and 3D-adhesions, pFAK or pSMAD2/3. This experiment assessed the precision of the SMI approach, and evaluated the extent of phenotypic similarities between the pancreatic and renal matrix-producing CAFs and normal fibroblastic systems in vitro. While normal pancreatic and renal 3D cultures included active αβ1-integrin that is mostly localized at 3D-adhesion sites.
Figure 11. Renal fibroblasts present a similar profile to pancreatic fibroblasts during matrix production. Fibroblasts were isolated from RCC surgical pathologically normal or tumoral samples, and their ECM-producing phenotypes were assessed after seven days of matrix production. (A) An integrin-dependent cell adhesion array test was used to assess the PM expression of integrin heterodimers in primary fibroblasts isolated from normal (white bars) vs. tumoral (dark bars) tissues. Note that no differences were apparent between the two cell types with regards to levels of $\alpha_v\beta_5$ and $\alpha_5\beta_1$.

Figure 11 continued on next page
integrins. (B) Normal vs. desmoplastic mRNAs levels, corresponding to αSMA and palladin (used as an additional myofibroblastic marker as before) were obtained via RT-qPCR from the indicated 3D-cultures following renal ECM (rECM) production, which was achieved via confluent culturing of fibroblasts in the presence of ascorbic acid for a period lasting 8 days (Franco-Barraza et al., 2016) (**p=0.0286). (C) Representative images of normal vs. desmoplastic phenotypes, subsequent to 3D rECM production, are shown; comparison of low vs. high αSMA levels (white), heterogeneous/round vs. elongated/spindled nuclei (yellow) and disorganized/isotropic vs. parallel aligned/anisotropic rECMs (magenta) are evident in the representative images.

DOI: 10.7554/eLife.20600.041

The following figure supplements are available for figure 11:

**Figure supplement 1.** rD-ECM production by rCAFs is TGFβ-dependent.

DOI: 10.7554/eLife.20600.042

**Figure supplement 2.** rD-ECM-induced renal naive-to-myofibroblastic activation is reminiscent of pancreatic D-ECM fibroblastic stellate cell activation.

DOI: 10.7554/eLife.20600.043

**Figure supplement 3.** FAK-independent αβ1-integrin activity negatively regulates rD-ECM-induced naive-to-myofibroblastic activation.

DOI: 10.7554/eLife.20600.044

**Figure supplement 4.** rD-ECM-induced increase in pFAK levels localized at 3D-adhesions are regulated by αβ3-integrin in naive renal fibroblasts.

DOI: 10.7554/eLife.20600.045

**Figure supplement 5.** rD-ECM regulates 3D-adhesion structure length, dependent on αβ1-integrin activity.

DOI: 10.7554/eLife.20600.046

**Figure supplement 6.** Naive renal fibroblastic cells increase overall levels of active αβ1-integrin in response to rD-ECM.

DOI: 10.7554/eLife.20600.047

---

**Table 5.** αSMA stress fiber localization and expression levels in naive renal fibroblasts cultured overnight within assorted renal ECMs.

| αSMA stress fiber localization | rN-ECM | rD-ECM | rD+TGFβi | rD+DMSO | TGFβi | DMSO | αβ5-i | αβ1-i | αβ1-act | IgG |
|------------------------------|--------|--------|----------|---------|-------|------|-------|-------|--------|-----|
| 25% percentile              | 0.05   | 0.88   | 0.28     | 0.689   | 0.87  | 0.91 | 0.46  | 0.63  | 0.74   | 0.96|
| Median                       | 0.29   | 1.00   | 0.72     | 0.89    | 1.03  | 1.05 | 0.67  | 0.89  | 1.00   | 0.93|
| 75% percentile              | 0.67   | 1.10   | 0.97     | 1.03    | 1.17  | 1.16 | 0.96  | 1.06  | 1.33   | 1.54|

Values obtained from naive renal fibroblastic cells cultured overnight within intact rD-ECMs (made from rCAFs) were used for normalization and assigned an arbitrary unit of 1.00. Assorted ECMs were intact rN-ECM or intact rD-ECM, while experimental conditions included D-ECMs made by CAFs treated with SB-431542 (rD+TGFβi) or DMSO (rD+DMSO) during ECM production. Experimental conditions during replating of naive cells within rD-ECM also included treatment with SB-431542 (TGFβi) or vehicle (DMSO) as well as treatment with ALULA (α5β1-i), mAb16 (α5β1-i), ALULA plus mAb16 (β3-α5-act), SNAKA (α5β1-act) or control pre-immune antibody (IgG). Note that quantitative values for αSMA and F-actin immunofluorescence were used to calculate stress fiber localization and expression of αSMA.

P values, listed below, were calculated using the two-sided and two-tailed Mann Whitney test needed for normalized data.

- rN-ECM vs. rD-ECM; p<0.0001 stress fiber localization
- rN-ECM vs. rD+TGFβi; p=0.0221 stress fiber localization
- rN-ECM vs. rD+DMSO; p<0.0001 stress fiber localization
- rD-ECM vs. rD+TGFβi; p=0.0058 stress fiber localization
- rD-ECM vs. rD+DMSO; p=0.1657 stress fiber localization
- rD+TGFβi vs. rD+DMSO; p=0.0630 stress fiber localization
- TGFβi vs. DMSO; p=0.7996 stress fiber localization

 DOI: 10.7554/eLife.20600.048
Having validated the seven-color SMI approach in vitro, we used the same technique, combined with SMIA-CUKIE analyses, on formalin-fixed paraffin embedded (FFPE) samples matching the original tissues from the five PDAC and four RCC patients used to generate the 3D stroma models analyzed in vitro (Figure 12—figure supplement 2). This analysis indicated clear increases in total α5β1-integrin activity, pFAK-Y397, and pSMAD2/3 in the stroma of PDAC and RCC compared to normal pancreatic and renal parenchyma (Figure 12—figure supplement 3A). When the same comparisons were performed for α5β1-integrin activity specifically localized away from stromal 3D-adhesion-positive pixels, the results again indicated clear increases (Figure 12—figure supplement 3B).

To determine whether this signature of CAF activation had prognostic value, we analyzed 128 PDAC and 126 RCC surgical specimens, using tissue microarrays (TMAs; Table 6). To establish baseline factors that are prognostic for survival, we initially evaluated the annotated clinical data for specimens on the TMAs (https://www.foxchase.org/sites/fccc/files/assets/cukierman_Franco-Barraza).
Table 6. PDAC and RCC cohorts included in TMAs.

|                | PDAC                  | RCC                   |
|----------------|-----------------------|-----------------------|
| **Samples**    | **Number**            | **Samples**           | **Number** |
| Tumor          | 128 (128 OS and 102 DSS) | Tumor                | 126 (116 OS and 115 DSS) |
| **Gender**     | **cases (%)**         | **Gender**            | **cases (%)**       |
| Female         | 76 (59.40)            | Female                | 34 (27)             |
| Male           | 52 (40.60)            | Male                  | 90 (71.4)           |
| N/A            | 0 (1.34)              | N/A                   | 2 (1.6)             |
| **Average age years** (range) | 67.51 (37–91) | **Average age years** (range) | 60.67 (23–82) |
| **TNM stage**  | **cases (%)**         | **TNM stage**         | **cases (%)**       |
| N              | 33 (25.80)            | 0                     | 99 (78.57)          |
| 0              | 91 (71.10)            | 1                     | 2 (1.59)            |
| 1              | 0 (0)                 | 2                     | 8 (6.35)            |
| 3              | 0 (0)                 | 3                     | 0 (0)               |
| N/A            | 4 (3.10)              | N/A                   | 17 (13.49)          |
| T              | **cases (%)**         | **T cases (%)**       | **cases (%)**       |
| 0              | 0 (0)                 | 0                     | 0 (0)               |
| 1              | 10 (7.81)             | 1                     | 38 (30.16)          |
| 2              | 34 (26.56)            | 2                     | 33 (26.19)          |
| 3              | 66 (51.56)            | 3                     | 44 (34.92)          |
| 4              | 13 (10.15)            | 4                     | 0 (0)               |
| N/A            | 5 (3.91)              | N/A                   | 11 (8.73)           |
| M              | **cases (%)**         | **M cases (%)**       | **cases (%)**       |
| 0              | 109 (85.16)           | 0                     | 85 (67.46)          |
| 1              | 6 (4.70)              | 1                     | 34 (26.98)          |
| N/A            | 13 (10.15)            | N/A                   | 7 (5.56)            |
| **Overall stage** | **cases (%)**       | **Overall stage**     | **cases (%)**       |
| I              | 17 (13.28)            | I                     | 32 (25.4)           |
| II             | 38 (29.69)            | II                    | 26 (20.63)          |
| III            | 53 (41.41)            | III                   | 25 (19.84)          |
| IV             | 14 (10.94)            | IV                    | 35 (27.8)           |
| N/A            | 6 (4.69)              | N/A                   | 8 (6.35)            |

N/A: Not available.
DOI: 10.7554/eLife.20600.053

%20SMIA-CUKIE-Dec-2016.xlsx) using univariate (Uni) and multivariate (MVA) analyses. For PDAC specimens, association between pathological N stage, overall pathological stage and positive nodes with overall survival (OS) indicated a significant increased risk of death correlated with increasing levels of these variables, with Uni hazard ratios (HRs) of 2.5 for pathological N (p=0.0002; 95% CI 1.5–4.2), 1.3 for pathological stage (p=0.01; 95% CI 1.1–1.6) and 1.15 for positive nodes (p=0.0001; 95% CI 1.1–1.2). Similar analyses looking at the association between clinical variables and recurrence-free survival (RFS) resulted in the identification of positive correlations for pathological N (HR = 2.1; p=0.009; 95% CI 1.2–3.7), pathological stage (HR = 1.4; p=0.01; 95% CI 1.0–2.0) and positive nodes (HR = 1.1; p=0.005; 95% CI 1.0–1.2). Further, MVA analyses for OS in PDAC specimens showed an association for N stage: HR = 1.9; p=0.06; 95% CI 1.0–3.6.
We then asked whether the levels and localization of the stromal biomarker signature developed here yielded clinically useful prognostic biomarkers for PDAC, testing the idea that stromal pSMAD2/3, indicative of TGF\(\beta\) signaling, would be associated with poor outcomes and active \(\alpha_\beta_1\)-integrin at 3D adhesions would be associated with better survival. For this, we conducted high-throughput SMI image acquisition and SMIA-CUKIE analysis of TMA PDAC samples, using univariate CART methodology to integrate the reporting levels of numerical outputs and intersections of the seven biomarkers of interest with OS or RFS. We observed significantly shorter OS in tumor surgical samples that had high stromal pSMAD2/3 values, whether values were quantified as mean or median stromal pSMAD2/3 intensity levels (Figure 13). Even though many patients did not show clinical improvement following surgery (so that our cohort presented a bias towards fast recurrence), high stromal pSMAD2/3 levels also correlated with shorter RFS (Figure 13—figure supplement 1). In addition, higher mean quantified levels of stromal \(\alpha_\beta_1\)-integrin activity also correlated significantly with longer RFS (Figure 13—figure supplement 2A). Interestingly, longer times to recurrence following surgery, quantified as the percentage area coverage relative to stromal occupied areas or as integrated intensities, were significantly associated with increased levels of integrin activity localized to stromal 3D-adhesion positive locations (Figure 13—figure supplement 2B).

These results suggest that stromal activation of TGF\(\beta\), represented by high stromal pSMAD2/3 levels and indicative of capacity for active production of D-ECM production, is a prognostic stromal trait for poor outcome, while increased stromal levels of active \(\alpha_\beta_1\)-integrin at 3D adhesion positive areas may constitute a patient-protective PDAC-associated desmoplastic phenotype.

To investigate whether these patterns are also seen in stroma associated with an additional epithelial cancer, we analyzed the RCC cohort (Table 6). Initial Uni and MVA analyses on the clinical data tested whether, in spite of the bias generated by the retrospective use of surgical cases, the cohort in question showed significant associations between pathological stages and OS and Disease-Specific Survival (DSS). Importantly, using CART analyses, we determined that RCC patients with high stromal levels of pFAK-Y\(^{397}\) localized at 3D-adhesions, higher nuclear pSMAD2/3, or increased levels of active \(\alpha_\beta_1\)-integrin, measured as mean, median or total stromal intensity levels as well as stromal percentage area coverages, had significantly shorter OS and DSS (Figure 13—figure supplements 3 and 4).

Together, these results strongly support the idea that the markers of an active desmoplastic phenotype, as defined herein, are useful in predicting patient outcomes.

Discussion

Understanding the activity of and clinically exploiting tumor-associated stroma have for a long time posed challenges, given strong evidence for both tumor-limiting and tumor-promoting stromal functionality (Mintz and Illmensee, 1975; Bissell and Hines, 2011; Langhans, 1879; Paget, 1889; Dvorak, 1986). The data in this study are useful by providing insight into stromal function in several ways. First, by addressing prior studies that suggest that changes in tumor-associated ECM are necessary for TGF\(\beta\)-dependent myofibroblastic activation (Desmoulière et al., 1993; Serini et al., 1998), they dissect the interaction of TGF\(\beta\) with N-ECM versus D-ECM. These results indicate that TGF\(\beta\) contributes to N-ECM assembly, and that it is essential solely for the phenotypic remodeling required for conversion to anisotropic D-ECM, but not for secretion of ECM components per se in the context of D-ECM production. This fact is supported by the observation that CAFs require TGF\(\beta\) signaling for the myofibroblastic production of anisotropic D-ECM and for expression of \(\alpha\)SMA, while the myofibroblastic features that are acquired by normal/naïve fibroblasts in response to D-ECM do not entail this signaling pathway. Second, our work addressed two cell-ECM receptor integrin heterodimers that have previously been shown to influence myofibroblastic activation, \(\alpha_\beta_5\) and \(\alpha_\beta_1\) (Asano et al., 2006; Lygoe et al., 2004; Dugina et al., 2001). Our study shows that both of these integrin heterodimers are abundant on the surface of both naïve fibroblasts and CAFs, but have distinct roles in the ability of naïve fibroblasts to respond to and of CAFs to assemble anisotropic D-ECM. In particular, our work integrated multiple approaches to emphasize an important role for \(\alpha_\beta_5\)-integrin in the response of naïve fibroblasts to D-ECM and for CAFs in producing anisotropic matrix. We also found that while \(\alpha_\beta_1\) counteracted the response of naïve fibroblasts to D-ECM, it was, not surprisingly, essential for matrix fibrillogenesis. Interestingly, in the context of extracted D-ECM imparting naïve-to-myofibroblastic activation, cross-signaling between the two.
integrins was apparent, with $\alpha_\beta_5$ regulating the internalization of part of the elevated pool of activated $\alpha_\beta_1$ to intracellular endosomal compartments (Figure 14). Third, we also defined specific ECM responses as independent of, or dependent on, the canonical integrin effector FAK. Fourth, importantly, we demonstrated that the signaling relationships identified in this study were valid in

Figure 13. Stromal pSMAD2/3 levels are predictive of poor overall survival in PDAC patients. (A) CART-generated survival curves depicting overall survival (OS) as a function of stromal pSMAD2/3 expression in PDAC patients. Left and right curves were obtained using mean and median intensity levels, generated by SMIA-CUKIE, of stromal pSMAD2/3 related to OS, respectively. (B) Survival curves depicting pathological N, stage, and node status with PDAC patient OS. Colored tick-lines crossing Y axes indicate 0.5 survival marks and correspond to X axes locations that mark the median survival times obtained from the assorted curves. P values are shown. All patient data as well as SMIA-CUKIE generated data corresponding to human cohort constructed TMAs (shown in Table 6) can be found in the online table at the following publically available link: https://www.foxchase.org/sites/fccc/files/assets/cukierman_Franco-Barraza%20SMIA-CUKIE-Dec-2016.xlsx. Note that since our cohorts comprised of samples obtained from surgeries, early neoplastic stages were overrepresented.

DOI: 10.7554/eLife.20600.054

The following figure supplements are available for figure 13:

Figure supplement 1. Stromal pSMAD2/3 levels are predictive of short recurrence-free survival in PDAC patients.
DOI: 10.7554/eLife.20600.055

Figure supplement 2. Stromal active $\alpha_\beta_1$-integrin levels localized at 3D-adhesions correlate with longer recurrence-free survival in PDAC patients.
DOI: 10.7554/eLife.20600.056

Figure supplement 3. Stromal levels and locations of p-SMAD2/3, active $\alpha_\beta_1$-integrin, and pFAK correlate with short overall survival in RCC patients.
DOI: 10.7554/eLife.20600.057

Figure supplement 4. Stromal levels and locations of p-SMAD2/3, active $\alpha_\beta_1$-integrin, and pFAK correlate with short disease specific survival in RCC patients.
DOI: 10.7554/eLife.20600.058
multiple model systems, including human primary PDAC and RCC, as well as additional murine models. Fifth, we used high-content imaging and data analysis to demonstrate that interactions analyzed in vitro can be used to define an in vivo stromal signature that has prognostic value, addressing a significant clinical goal.

There is strong evidence for desmoplastic stromal reciprocation, involving altered ECM (e.g., D-ECM) and adjacent tumor and/or stromal cells during PDAC development and progression (Xu et al., 2009; Tape et al., 2016; Alexander and Cukierman, 2016; Garcia et al., 2014; Roskelley and Bissell, 1995). Several prior studies have searched for proteomic signatures of normal vs. tumor-affected stroma (Webber et al., 2016), in order to identify stromal traits that are associated with favorable or unfavorable clinical outcomes (Erkan et al., 2008; Moffitt et al., 2015). Some of these signatures have been proposed to serve as clinically relevant tumor sub-type indicators (Choi et al., 2014). The desmoplastic 3D models used in this study allowed us to functionally dissect both mechanisms of D-ECM production by CAFs, including the specific induction of anisotropic ECMs, and D-ECM-induced responses such as myofibroblastic activation of naïve fibroblasts, mechanistically informing the significance of such signatures.

A role for TGFβ in regulating the production of anisotropic ECM had been previously suggested (Khan and Marshall, 2016). Remodeling that causes isotropic ECMs to become increasingly anisotropic, together with increases in matrix tension and stiffness, are all features of chronic fibrosis that
physically enhance the accessibility and activation of TGFβ by myofibroblastic integrins (Klingberg et al., 2014). Another interesting study demonstrated that substrate stiffness influences the ability of a cell induced in vitro to undergo myofibroblastic activation, and can positively or negatively influence the degree to which a cell is able to accurately acquire the characteristics (Achterberg et al., 2014) of a CAF in vivo. In accord with this line of thinking, one may argue that specific ECM topographies, and in particular the overall physical properties of cell substrates, play key pathophysiological roles in promoting positive feedback loops involving myofibroblastic cells and D-ECMs in fibrous tumor-associated microenvironments, such as PDAC-associated desmoplasia (Alexander and Cukierman, 2016). Our results indicated that while TGFβ is necessary for normal fibroblasts to assemble N-ECM, it is essential solely for the phenotypic remodeling of anisotropic D-ECM by CAFs, and not for its production. Negating CAF capability to produce anisotropic D-ECM restricts tumor growth in vivo (Goreczny et al., 2016), while increased levels of anisotropic D-ECM correlate with poor patient survival and cancer relapse (Goetz et al., 2011; Conklin et al., 2011; Bredfeldt et al., 2014). Inhibition of the TGFβ type I receptor, which reduces the activity of a downstream canonical effector of TGFβ, SMAD2/3, is known to hinder matrix fibrillogenesis (Callahan et al., 2002). In our work, elevated fibroblast-expressed pSMAD2/3 and nuclear translocation of this protein in CAFs producing D-ECM correlated with short time to recurrence and reduced survival in both PDAC and RCC patient cohorts. Results from our study also suggest that while TGFβ-targeted therapeutic interventions may revert D-ECMs to their naturally tumor-suppressive isotropic phenotype, the same approach could ablate homeostatic N-ECM. Consideration of this possibility is important because total ablation of TGFβ induces multifocal inflammatory disease (Shull et al., 1992) and because clinical trials are currently assessing TGFβ-inhibitory drugs (Herbertz et al., 2015).

While the understudied αvβ1 heterodimer was recently recognized as a regulator of latent TGFβ in fibrosis (Reed et al., 2015), αvβ5 and αvβ1 integrins are involved in myofibroblastic activation (Asano et al., 2006; Lygoe et al., 2004; Dugina et al., 2001). Both αvβ1 and αvβ5 integrin receptors were abundant in primary fibroblasts collected from patients. Our results demonstrated that in response to D-ECM, αvβ5-integrin activity supports the relocalization of active αvβ5-integrin to intracellular endosomal pools and that this vesicular accumulation is needed for the maintenance of naïve-to-myofibroblastic activation. In addition, genetic loss (but not transient inhibition) of αvβ1, which resulted in slow-growing naïve cells, altogether prevented de novo D-ECM induction of naïve-to-myofibroblastic transition. Interestingly, in other studies, αvβ1-positive elongated ‘super mature’ adhesion structures (Dugina et al., 2001; Hinz et al., 2003), which control tension-dependent recruitment and retention of αSMA at stress fibers, were found to play a functional role in myofibroblastic activation (Goffin et al., 2006). Together with our findings, these data suggest that αvβ1 participates in the regulation of αSMA expression, whereas the αvβ5-regulated relocation of activated αvβ1-integrin participates in αSMA localization to stress fibers. Other studies have shown that inhibition of αvβ5-integrin activates β1-integrin, counteracting ECM-dependent myofibroblastic αSMA stress fiber localization (Wang et al., 2012). However, the nature of the specific β1-integrin heterodimer and the mechanistic details of this negative myofibroblastic regulation were previously unknown. We further defined the α5β1 activity that regulates αSMA localization as independent of FAK. Interestingly, a previously defined α5β1 integrin activity needed to form 3D-adhesions in both normal cell-derived ECMs and in vivo is also FAK-independent (Cukierman et al., 2001).

Intriguingly, our results indicate that D-ECM induces αvβ5-integrin-dependent redistribution of active αvβ5-integrin to intracellular pools, within structures that include CD81-positive multivesicular (Escola et al., 1998) and late Rab7/Rab11 endosomes. We found that using SNAKA51 to stabilize αvβ5-integrin activity resulted in reduced internalization, a finding that differs from results reported previously which indicated that treating cells with SNAKA51 internalized active integrin (Mana et al., 2016). It is possible that these differences reflect differences in analytic time points. Mana et al. (2016) looked at a time point of 20 min after treatment, whereas we analyzed data after overnight incubation with SNAKA51, which may have led to compensatory enrichment of activity at the PM in our study, and thus further investigation is required. However, it is interesting that engagement of the integrin-binding ligands RGD, osteopontin and cilengitide with αvβ5 and αvβ1 results in the association of αvβ1 with a Rab-coupling protein which regulates its localization concomitant with EGFR (Caswell et al., 2008). It is therefore possible that the use of ALULA (Clark et al.,
in this study triggered activation of the Rab cellular trafficking machinery, in a manner restricted by α5β5 activity during tumor-associated desmoplasia.

The importance of identifying reliable biomarkers for early PDAC diagnostics (Laeseke et al., 2015) and improved RCC prognostic predictions is clear. Recently, increased stromal density was deemed to be a better prognostic outcome in a retrospective study looking at pancreatic cancer patients who underwent pancreaticoduodenectomy followed by adjuvant treatment, while assessing overall levels of stromal αSMA was found to be inconclusive (Bever et al., 2015). In the future, it will be interesting to test whether the increased stromal density, perhaps in the context of specific relocalization of αSMA, corresponds to this study’s ‘patient-protective’ phenotype. This example, together with additional studies that suggest both tumor-protective and -detrimental roles for highly heterogeneous desmoplasia (Özdemir et al., 2014; Rhim et al., 2014; Sherman et al., 2014; Bever et al., 2015; Dekker et al., 2015; Sasson et al., 2003), underscores the need for better stromal categorization. The new software developed in this study to facilitate analysis of the discrete localizations of the various markers specifically in stroma (freely downloadable from https://github.com/cukie/SMIA_CUKIE) allows analysis of batch-sorted monochromatic images in bulk, and generation of qualitative and quantitative outputs to evaluate biomarkers located at any given mask and/or marker intersection. In this study, we used this software to identify predictive biomarker signatures for PDAC and RCC patients. Stromal increases in pSMAD2/3 and pFAK correlated with worse outcomes but, in spite of the bias introduced by the use of resectable surgical cases, we identified a patient-protective stroma phenotype in PDAC, in which increased active α5β1-integrin selectively localized at stromal 3D-adhesions is associated with improved outcomes. By contrast, intensities of active α5β1-integrin activity correlated with increasingly unfavorable OS as well as DSS in RCC patients. Hence, locations and intensities of stromal α5β1-integrin activity concomitant with constitutive active pFAK-Y397 could represent novel desmoplasia-dependent outcome-predicting stromal patterns. As our in vitro studies suggested a complex function for α5β1-integrin activity, and given the differences between the molecular characteristics of distinct tumor subtypes, we emphasize that individual tumor classes will require careful study before these biomarkers could be used as predictive clinical indicators.

In summary, our study provides new insights into the intracellular and extracellular signaling processes that support desmoplastic formation, with mechanistic studies facilitated by the use of in vitro fibroblast-derived 3D ECMs. Specifically, the results suggest that α5β1-integrin prevents FAK-independent α5β1-integrin activity from impairing D-ECM-induced naïve-to-myofibroblastic activation by relocalizing this activity to multivesicular and other late endosomes. β3-integrin’s contribution to the ability of CAFs to produce functional anisotropic D-ECM, in which active α5β1-integrin levels are not altered, distinguishes between naïve-to-myofibroblastic activation and myofibroblastic CAFs. Importantly, this study supports the idea that stromal normalization, to produce a form that plays a tumor-suppressive role (Mintz and Illmensee, 1975; Soto and Sonnenschein, 2011; Xu et al., 2009; Bissell and Hines, 2011; Alexander and Cukierman, 2016) may be a favorable approach, especially as some recent attempts aimed at completely abolishing stroma have proven harmful to patients (Bijlsma and van Laarhoven, 2015; Özdemir et al., 2014; Rhim et al., 2014). This work also suggests specific protein targets that may be useful for stroma-normalizing therapies. For example, these data suggest that future therapeutic strategies might involve combinatorial treatments to inhibit TGFβ and α5β5-integrin. Finally, the study also suggests that monitoring the level and localization of stromal pSMAD2/3, as well as those of α5β1-integrin activity together with those of stromal pFAK, could assist in stratifying individuals that would benefit from α5β5-integrin and other chronic fibrosis-directed therapeutics.

Materials and methods

Ethics statement

Human tissues were collected under exemption-approval of the Center’s Institutional Review Board after patients signed a written informed consent agreeing to donate samples to research. To protect patients’ identities, samples were coded and distributed by the Institutional Biosample Repository Facility.
Reagents and cell lines
All reagents (see below) were from Sigma-Aldrich (St. Louis, MO) unless listed otherwise. All primary and immortalized fibroblasts were cultured at 37°C under 5% CO₂ using Dulbecco’s Modified Eagle’s Medium (Mediatech (Manassas, VA)) supplemented with 10% or 15% (murine or human cells, respectively) Premium-Select Fetal Bovine Serum (Atlanta Biologicals (Lawrenceville, GA)), 2 mM L-glutamine and 100 u/ml-µg/ml penicillin-streptomycin. Panc1, FAK⁺/⁺, FAK⁻/⁻, SYF, and littermate wild-type control cells were from the American Tissue Culture Collection (Manassas, VA). FAK-KD and hTert controls were a gift from David Schlaepfer (UCSF, San Francisco, CA).

A request to annotate the human fibroblastic cell lines that were generated in this study was issued to the Research Resource Identifiers for their quarterly year annotations. Also, these cells were submitted for CellCheckTM 16 Marker STR Profile and Inter-species Contamination Test for human cell line authentication to IDEXX Bioresearch (Columbia, MO). Markers evaluated to authenticate the diversity of cell origins (patients) were: AMEL, CSF1PO, D13S317, D16S539, D18S51, D21S11, D3S1358, D5S818, D7S820, D8S1179, PGA, Penta_D, Penta_E, TH01, TPOX, and vWA. Interspecies contamination testing included comparison of human samples versus mouse, rat, Chinese hamster and African green monkey DNA. Mycoplasma contamination status was negative. This study did not utilize cell lines listed in the Database of Cross-Contaminated or Misidentified Cell Lines (Version 7.2) from the International Cell Line Authentication Committee (ICLAC).

Isolation and characterization of fibroblastic cells
Pan-keratin (AE1/AE3 - Dako (Carpinteria, CA)) negative and vimentin (EPR3776 - Abcam (Cambridge, MA)) positive fibroblastic cells were isolated from fresh surgical normal and tumoral tissue samples using the enzymatic tissue digestion approach as published (Franco-Barraza et al., 2016). Fresh surgical tissues from normal or tumoral pancreas and from kidney or murine skin (see below) were collected into conical tubes containing Dulbecco’s phosphate-buffered saline with antibiotics at 4°C. Samples were minced and subjected to overnight gelatinase digestion. Digested tissues were subjected to 10 min 200 g centrifugation followed by three sequential size-exclusion filtrations using sterile nylon mesh strainers of pore sizes 500 µm, 100 µm and 40 µm. The resulting cells were characterized as naive or CAFs according to methods reported previously (Gupta et al., 2011; Goetz et al., 2011; Amatangelo et al., 2005). Cells were used for no longer than 12 passages while maintained within their own derived ECMs (if cells were not to be maintained in 3D ECMs, only 4–6 passages would have been used).

Fibroblasts used in the study were harvested from five different patients for PDAC (including two matched pairs) and four for RCC models, while the fibroblasts used for the murine model of skin squamous-cell-carcinoma-associated desmoplasia were from our published study in which the D-ECM-induced naïve-to-myofibroblastic transition was first described (Amatangelo et al., 2005). Note that PDAC fibroblastic cells from patient #1 were used in vitro throughout the study unless stated otherwise.

Preparation of fibroblast-derived 3D ECMs
We obtained cell-derived ECMs using our published protocols (Franco-Barraza et al., 2016). Confluent fibroblastic cultures were maintained for 7 days in the presence of daily added and freshly prepared ascorbic acid at a concentration of 50 µg/ml. The resulting ‘unextracted’ 8 day long multilayered 3D cultures were used as naïve or CAF-matrix—producing cultures in this study and were processed for phenotypic characterization and ECM alignment (isotropy vs. anisotropy assessments). Cell extraction, to obtain N- and D-ECMs, was achieved using 0.5% (v/v) Triton X-100 complemented with freshly added 20 mM NH₄OH. Extracted N- and D-ECMs were stored sealed, using Parafilm, in culturing plates with Dulbecco’s phosphate-buffered saline lacking CaCl₂ and MgSO₄ at 4°C. The resulting extracted matrices were used for D-ECM-induction of naïve-to-myofibroblastic activation. For the production of 3D matrices using inhibitors, the following were added during the 7 days of ECM production: TGFβ1R small molecule inhibitor (SB431542) (25 µM); DMSO; conformation-dependent anti-active α₅-integrin functional antibody (Clark et al., 2005) (45 µg/ml SNAKA51 [a gift from Martin Humphries, Manchester University, UK]); functional-blocking anti-α₅β₅-integrin (Clark et al., 2005) (60 µg/ml ALULA [a gift from Drs Dean Sheppard (UCSF, San Francisco, CA),...
and Shelia Violette (Biogen, Cambridge, MA); or species-matched non-immunized isotypic antibodies.

**RT-qPCR**

The Ambion PureLink kit (Life Technologies) was used, according to manufacturer’s instructions, to extract total cellular RNA from the various experimental conditions and tested for RNA quality using a Bioanalyzer (Agilent). Contaminating genomic DNA was removed using Turbo DNA free from Ambion. RNA concentrations were determined with a spectrophotometer (NanoDrop; Thermo Fisher Scientific). RNA was reverse transcribed (RT) using Moloney murine leukemia virus reverse transcriptase (Ambion) and a mixture of anchored oligo-dT and random decamers (IDT). Two reverse-transcription reactions were performed for each experimental duplicate sample using 100 ng and 25 ng of input RNA. Taqman assays were used in combination with Taqman Universal Master Mix and run on a 7900 HT sequence detection system (Applied Biosystems). Cycling conditions were 95°C, 15 min, followed by 40 (two-step) cycles (95°C, 15 s; 60°C, 60 s). Ct (cycle threshold) values were converted to quantities (in arbitrary units) using a standard curve (four points, four-fold dilutions) established with a calibrator sample. Values were averaged per sample and standard deviations were from a minimum of two independent PCRs. Polymerase (RNA) II (DNA directed) polypeptide F (POLR2F) was used as internal control. Identification numbers of commercial assays (Life Technologies) and sequences of the primers and probe for the POLR2F assay are: Hs00363100_m1 (PALLD1), Hs00426835_g1 (ACTA2), TGCCATGAAGGAACTCAAGG (forward), TCATAGCTCCCATCTGGCAG (reverse), and 6fam-CCCCATCATCATTCCGTCGTTACC-bqh1 (probe).

**D-ECM prompted naïve-to-myofibroblastic activation**

Human naïve or assorted murine fibroblasts were pre-incubated for 45 min with functional antibodies, small molecule inhibitors or controls, prior to overnight culturing within assorted ECMs. Experiments were carried out in the presence or absence of 45 µg/ml SNAKA51 (Clark et al., 2005), 60 µg/ml ALULA (Su et al., 2007), 250 µg/ml mAb16 (Akiyama et al., 1989) (a gift from Kenneth Yamada [NIDCR/NIH, Bethesda, MD]), BMAS (Fehlner-Gardiner et al., 1996) diluted as instructed by the manufacturer (Millipore, Temecula, CA), IgG control, DMSO, or small molecule inhibitor of FAK (PF573,228 [Slack-Davis et al., 2007]). ECM-induced phenotypes were assessed by RT-qPCR, western blot or immunofluorescence as described in the corresponding Methods sections.

**Array to detect constitutive plasma-membrane-localized levels of assorted β-integrin heterodimers**

An integrin-mediated cell adhesion assay was conducted to detect cell surface levels of heterodimeric integrin receptors on the assorted fibroblastic cells. The array, ECM531 from Millipore, is based on the use of selected monoclonal antibodies against assorted β-integrin heterodimers and testing amounts of cell adhesion to each particular antibody. Cells are incubated onto an array of wells coated with the various antibodies and then washed, while adherent cells are counted. The number of cells adhering to a specific antibody is directly related to the amount of the specific integrin receptor expressed at the cell surface. Numbers of adherent cells’ surfaces are evaluated by 540–570 nm absorbance of cells stained using a staining reagent provided with the kit according to the manufacturer’s instructions.

**TGFβ ELISA**

Quantification of TGFβ stored/deposited into unextracted fibroblast 3D cultures was performed using the DuoSet human TGFβ1 ELISA kit, as instructed by the manufacturer (R and D Systems, #DY240-05). All wash buffers and reagents were provided in the DuoSet Ancillary Reagent Kit 1 (R and D systems, #DY007). Briefly, whole cell lysates (or conditioned media as controls) were obtained from fibroblasts and loaded onto plates that were pre-coated with capture antibody overnight at RT. After 2 hr incubation of lysates, concentrated media and calibration curve standards, wells were rinsed three times with wash buffer and then incubated for 2 hr at RT with detection antibody. Next, after three more washes, streptavidin-HRP was incubated in the wells for 20 min at RT. After another three washes, substrate solution was added to the wells, and after 15 min, stop solution was added to halt the HRP-substrate reaction. Next, OD at 450 nm and 570 nm was obtained using the Synergy
H1 plate reader (BioTek). The OD at 570 nm was subtracted from the OD at 450 nm to correct for plate imperfections. Then the standard curve was constructed, and the concentration of TGFβ (pg/mL) in experimental samples was determined. Last, TGFβ concentration was normalized to the amount of protein loaded into each well and then normalized to control TAF levels, with the modal value referred to as one a.u. (arbitrary unit).

**Electron microscopy**

Au8-SNAKA51 and Au15-mAb11 gold-antibody complexes were conjugated as described in *Handley et al.* (1981). Cells from functional assays were fixed with 2.0% paraformaldehyde in PBS, pH 7.4, at 4°C overnight. Following antibody incubation, cells were fixed with 2.0% glutaraldehyde washed and post-fixed in 2.0% osmium tetroxide for 1 hr at room temperature. Dehydration through a graded ethanol series and propylene oxide was followed by embedding samples in EMBed-812 (Electron Microscopy Sciences [Hatfield, PA]). Sections were stained with 2% alcoholic uranyl acetate and scanned with a FEI Tecnai electron microscope, while images were acquired using a Hamamatsu digital camera operated via AMT Advantage image capture software (AMT 542.544; 18 Sep 2009).

**Indirect immunofluorescence (in vitro)**

The method for indirect immunofluorescence was as published previously (Gupta et al., 2011; Amatangelo et al., 2005; Franco-Barraza et al., 2016; Cukierman et al., 2001), only Triton was omitted for non-permeable conditions. Samples were either fixed/permeated or solely fixed as published (Franco-Barraza et al., 2016). Following 60 min blocking, using Odyssey Blocking Buffer (LI-COR Biosciences, Lincoln, NE) containing 1% donkey serum, the following primary antibodies were incubated in combinations as indicated by the specific experiments for a period of 60 min: anti-pan-cytokeratin (clones: AE1/AE3) (AB_2631307) from Dako (Carpinteria, CA), rabbit monoclonal anti-Vimentin EPR3776 (AB_10004971) (1:200) from Abcam (Cambridge, MA), rabbit polyclonal anti-human fibronectin (AB_476961) (1:200) and 1 A4 mouse anti-αSMA (AB_476701) (1:300) were from Sigma-Aldrich (St. Louis, MO), mouse SNAKA51 Ab (45 μg/ml) was a gift from M Humphries (Clark et al., 2005), rat mAb11 (45 μg/ml) from K Yamada (Akiyama et al., 1989), rabbit polyclonal anti-palladin (AB_2158782) (1:200) (Proteintech, Chicago, IL), rabbit monoclonal anti-phospho FAK [Y397] (AB_2533701) (1:200) (Invitrogen, Camarillo, CA), rabbit monoclonal anti-phospho Smad2 [S465/467]/Smad3 [S423/425] (AB_2631089) (1:200) (Cell Signaling, Danvers, MA), rabbit monoclonal anti-Rab5 (AB_10828212) (1:150) (Cell Signaling, Danvers, MA), rabbit monoclonal anti-Rab7 (AB_10831367) (1:25) (Cell Signaling, Danvers, MA), rabbit monoclonal anti-Rab11 (AB_10693925) (1:25) (Cell Signaling, Danvers, MA), rabbit monoclonal anti-EEA1 (1:150) (AB_10828484) (Cell Signaling, Danvers, MA), rabbit monoclonal anti-CD81 (AB_2275892) (1:35) (Santa Cruz Biotechnologies, Dallas, Texas) and species-matched non-immunogenic mouse IgG (Abcam) and Rat IgG (Jackson ImmunoResearch Inc., West Grove, PA) were used at equal concentrations to their corresponding matching isotypes. Following three rinses of 5 min with PBS-Tween20 (0.05%), secondary antibodies were incubated for 60 min using donkey F(ab’)two fragments (1:100) cross-linked to assorted fluorophores (Jackson ImmunoResearch Laboratories Inc.). When mentioned, SYBR Green (1:10,000 Invitrogen [Eugene, OR]) or Draq-5 (1:10,000 Pierce Biotechnology [Rockford, IL]) and/or fluorescent Phalloidin (2.5 μl/100 μl, Invitrogen [Eugene, OR]) were included. Following washes with PBS and a final rinse with double-distilled water, samples were mounted using Prolong Gold anti-fading reagent from Life Technologies (Carlsbad, CA). When needed, anti-αSMA and/or SNAKA51 primary antibodies were pre-linked to fluorescent dye crystals using the Mix-n-Stain™ kit following the manufacturer’s recommendations (Biotium, Hayward, CA).

**Confocal image acquisition**

Confocal spinning disk Ultraview (Perkin-Elmer Life Sciences, Boston, MA) images were acquired with a 60X (1.45 PlanApo TIRF) oil immersion objective, under identical exposure conditions per channel using Velocity 6.3.0 (SCR_002668) (Perkin-Elmer Life Sciences, Boston, MA). Maximum reconstruction projections were obtained using MetaMorph 7.8.1.0 (SCR_002368) (Molecular Devices, Downingtown, PA) as described previously (Amatangelo et al., 2005). For monochromatic in vitro image analyses using SMIA-CUKIE, please refer to SMI methods below.
**ECM fiber orientation analysis**

Fibronectin channel monochromatic images were analyzed via ImageJ's (SCR_003070) OrientationJ plugin (SCR_014796) [http://bigwww.epfl.ch/demo/orientation/] (Franco-Barraza et al., 2016; Rezakhaniha et al., 2012). Numerical outputs were normalized by setting mode angles to 0˚, and correcting angle spreads to fluctuate between −90˚ and 90˚. Angle spreads for each experimental condition, corresponding to a minimum of three experimental repetitions and five image acquisitions per condition were plotted and their standard deviations calculated using Excel spreadsheets. Percentage of fibers oriented between −15˚ and 15˚ was determined for each normalized image-obtained data. See statistics section below.

**Digital imaging analyses (in vitro)**

16 bit TIFF files corresponding to the maximum projections of assorted monochromatic reconstituted z-stacks were analyzed using MetaMorph Offline software. On the basis of a noise/signal ratio, gray-scale levels of reference images (control) were optimized to reduce background to a minimum while avoiding signal saturation (at the maximum point). An inclusive threshold for positive signal was set for control images. These levels and threshold values were used throughout the entire experiment and served as normalizing controls for each experiment.

Intensity levels of αSMA or active α5-integrin were determined by threshold-masked images, evaluating total pixel intensities and integrated optical densities, using corresponding functions from the software’s integrated morphometry analysis (IMA) algorithm. The percentage of αSMA colocalization at F-actin stress fiber structures was calculated by querying αSMA-positive area coverages that overlapped (i.e., co-localized) with phalloidin-positive stress fibers areas.

For experiments questioning levels in murine cells, an ‘activated fibroblastic phenotype’ was determined by counting the percentage of cells presenting stress-fiber-localized αSMA. Output data from each analysis were normalized to corresponding control conditions and expressed as fold variations related to control.

For 3D-adhesion length calculations: calibrated images (one pixel = 0.11 μm) were used while their gray-scale levels were optimized to reveal 3D-adhesion (i.e., mAb11) positive-stained structures. These were recognized as ‘objects’ by the software via threshold settings (identical for all images) and measured through the ‘dimension’ function of IMA. Objects with lengths ≥6.5 μm, signifying bona fide 3D-adhesion structures (Cukierman et al., 2001), were included in the analysis.

The more intricate analyses of multi-labeled 3D-adhesions were performed using the ‘line-scan’ function of the software. Channel-overlaid 8bit images were subjected to a transversal analysis (12 μm length) to identify peaks of median gray levels of the stated particular markers along the line-scanned structure being analyzed.

**Simultaneous multi-channel immunofluorescent (SMI) approach and SMIA-CUKIE software-based analyses**

Conjugation of Q-dot to primary antibodies
Q-dot antibody labeling kits were from Molecular Probes-ThermoFisher Scientific. SiteClick labeling constitutes a three-step procedure lasting a few days and requires that the desired antibody’s carbohydrate domain is modified to allow an azide molecule to be attached to it; In consequence, DIBO-modified nanocrystals are linked to the antibody in question. Each conjugation was carried out strictly as instructed by the protocols provided by the manufacturer. Briefly, approximately 100 μg of antibody was used in each case. Unless there were excessive carrier proteins present in the antibody, there was no need for an antibody pre-purification step. The labeled antibodies were...
estimated to be at 1 μmolar concentration and stored in sterile conditions at 4°C in light-protected boxes. Sample incubations were all done at a final concentration of ~20 nM or 1:50 dilution (see below).

Immunolabeling of FFPE tissue sections
Slides were exposed to a short-wave UV lamp for about 30 min in a light-protected box to quench auto-fluorescence. They were then kept in a light-protected (i.e., dark) box until used. Sections were deparaffinized in xylene and rehydrated in ascending graded alcohol to water dilutions. Sections were then treated with Digest-All (Invitrogen) and permeabilized in 0.5% TritonX-100. After treating them with blocking buffer as in in vitro work (see above), samples were first incubated with the above-mentioned Q-dot pre-labeled antibodies (i.e., Q655 SNAKA51, Q565 mAb11) overnight at 4°C. Sections were washed as in in vitro work, and incubated with a mix of mouse monoclonal 'cocktail' containing anti-pan-cytokeratin (clones AE1/AE3, DAKO), anti-EpCam (MOC-31EpCam, Novus Biologicals (Littleton, CO)), and anti-CD-70 (113–16 Biolegend (San Diego, CA) [Ryan et al., 2010]) to detect epithelial/tumoral locations, together with rabbit monoclonal anti-vimentin (EPR3776, Abcam) antibodies for mesenchymal (stromal) components for 2 hr at RT. Note that pre-incubated Q-dot labeled antibodies could no longer be recognized by secondary antibodies, thus allowing for indirect immunofluorescent detection of tumoral and stromal masks. Secondary antibodies were as used as in in vitro work and included donkey anti-mouse Cy2 and donkey anti-rabbit Cy3. Nuclei were stain using Draq-5 (as in vitro). Sections were quickly dehydrated in graded alcohol and clarified in Toluene before mounting in Cytoseal-60. Slides were cured overnight at RT before the imaging.

Image acquisitions of FFPE fluorescently labeled sections
FFPE sections of biological samples are known to give strong broad autofluorescence, thus obscuring the specific (labeled) fluorescent signal. To overcome this problem, images were collected using Caliper’s multispectral imaging system (PerkinElmer), which utilizes a unique imaging module with Tunable Liquid Crystal. Two different systems namely Nuance-FX (for 40x objective) and Vectra (for 20x objective and high throughput) were used depending on the acquisition needs. A wavelength-based spectral library for each system and each tissue type (i.e., pancreas and kidney) was created by staining control sections with individual fluorophores or by mock treating samples to include the specific autofluorescence spectra. Once a spectral library was constructed for each organ type, it was saved and used for the subsequent image acquisition and analysis. All excitations were achieved via a high-intensity mercury lamp using the following filters (emission-excitation): for Nuance, DAPI (450–720), FITC (500–720), TRITC (580–720), CY5 (680–720); for Vectra, DAPI (440–680), FITC (500–680), TRITC (570–690), CY5 (680–720). For emissions collection, ‘DAPI’ filter (wavelength range 450–720) was used for all Q-dot labeled markers, while masks used the conventional FITC, TRITC, and CY5 filters. After collecting all image cubes (including all channels), images were unmixed to obtain 16-bit greyscale individual stains monochromatic files. Using Photoshop’s ‘Levels’ and ‘Batch Conversion’ functions, the images were processed in bulk to render identically scaled 8-bit monochromatic images for each channel. The resulting images were sampled to set identical threshold values for each channel, which were used to feed the values needed for analyses in SMIA-CUKIE to signify positive-labeled pixels.

SMIA-CUKIE usage and outputs
SMIA-CUKIE (SCR_014795) was written for the bulk analysis of high-throughput-acquired monochromatic images, corresponding to simultaneously labeled channels like the ones used in this study. As examples, masks in Figure 12 and Figure 12—figure supplement 2 were generated using SMIA-CUKIE and demonstrate how the software isolates stromal locations while omitting positive tumoral areas, based on mask value thresholds that are provided by the user.

Images were sorted into ‘Batch Folders’, each containing the five monochromatic images corresponding to the original (unmixed) sample. The newly written software, available at https://github.com/cukie/SMIA_CUKIE, was created to bulk process and analyze batches of monochromatic images providing localization (masks), intensities, and similar quantifying values (markers), including co-localizations of multichannel monochromatic immunofluorescent (or IHC, etc.) images. The software can...
identify intersection areas between an unlimited amount of masks, while queried marker values and locations can also be estimated for numerous interrogations. The software requires the identification of common nomenclatures to recognize each type of monochromatic image (i.e. vim for vimentin etc.). It also needs information regarding the available number of masks and markers deposited in the batch folders containing the images. In this work, three masks were used corresponding to nuclei, epithelium/tumor and stroma, as well as two markers corresponding to adhesion structures and active α5β1 integrin. For each of the masks and markers, the software requires a numeric threshold (0-255), which indicates the value of pixel intensity that is to be considered positive for each channel (corresponding to each mask and marker). The software then allows choosing amongst all possible query combinations. Alternatively, it provides an option for the user to write the desired tests to be queried. For example, when active α5β1 integrin values were requested at bona fide stromal locations, the software was instructed to look for ‘SNAKA under vimentin, NOTepi/tumor’. In this example, ‘SNAKA’ was the nomenclature we used for the active integrin channel while vimentin and epi/tumor served as masks. After running this function, the software rendered an Excel file containing values of area coverage for the marker at the requested mask intersection (stroma), as well as total area coverage related to the image. Similarly, values included mean, median, standard deviation, total and integrated intensities. In addition, the software can be instructed to provide image outputs corresponding to requested mask locations, as well as markers shown solely at the corresponding mask intersections (as shown in Figure 12 and Figure 12 –figure supplement 2). Data values obtained in this work are available online at https://www.foxchase.org/sites/fccc/files/assets/cukierman_Franco-Barraza%20SMIA-CUKIE-Dec-2016.xlsx. Finally, values were used for statistical analyses as described in the corresponding section.

**CRISPR/CAS9-mediated knockout of β5 and other integrins in fibroblasts**

Immortalization of human fibroblasts

Before performing CRISPR/Cas9-mediated KO of β5 integrin, fibroblasts were immortalized with human telomerase (hTERT) (Counter et al., 1998), using a retroviral infection with the pBABE-neo-hTERT vector, which was a gift from Robert Weinberg (Addgene plasmid # 1774). First, in order to produce functional retrovirus, packaging cells Phoenix-Amphotropic (jNX) (ATCC # CRL-3213) at 50% confluence in 10 cm culture dishes were transfected with 10 ug pBABE-neo-hTERT vector using 10 uL Lipofectamine (Invitrogen, #18324) and 40 uL of Plus Reagent (Invitrogen, # 11514015) in 6 mL serum/antibiotics free Opti-MEM (Gibco, # 31985062) culture media overnight at 37°C in a cell culture incubator. The following morning, the medium was replaced with 10 mL fresh Opti-MEM (serum/antibiotics free) and incubated 24 hr at 32°C. In the morning of days 2, 3 and 4 post-transfection, the conditioned medium containing retrovirus was collected and filtered through a 0.45 um syringe filter (Millipore, #SLHV013SL) and used for subsequent retroviral transfections of fibroblasts. For the viral infection, fibroblasts were cultured in 10 mL of conditioned medium containing the retrovirus (supplemented with 4 ug/mL Polybrene (Santa Cruz, #sc-134220)) for 8 hr at 37°C. Then cells were washed and incubated with fresh culture medium (DMEM 10% FBS, 1% L-Glut, 1% P/S) and incubated at 37°C overnight. Beginning the next day, this infection procedure was repeated two additional times, for a total of three retroviral infections. Fibroblasts were then selected with G-418 at a concentration of 750 μg/mL until cells grew back to ~90% confluence. Cells were then expanded and tested for overexpression of hTERT, and lack of p16, by western blotting to confirm hTERT overexpression. These cells were used for CRISPR/CAS9-mediated knockout of β5 integrin.

**gRNA design**

To knockout the β5-integrin-subunit-encoding gene from fibroblasts, CRISPR/CAS9 gene editing was performed to introduce a frameshift mutation that disrupts the reading frame causing a premature stop codon to be read, ultimately halting translation and knocking out this gene. First, gRNAs specific for β5 integrin were designed by targeting exon 3. The first 200 base pairs of exon three were inserted into MIT Optimized CRISPR Design website: http://crispr.mit.edu/ and the top two scoring gRNAs were selected, based on the presence of a PAM site (a CAS9 recognition site) and limited off-target binding.

The two independent gRNA sequences were as follows:
gRNA1: ACCGAGAGGTGATGGACCGT
gRNA 2: CACCGAGAGGTGATGGACCG

For a non-targeting gRNA control, the following gRNA against eGFP was designed: CATGTGATCGCGCTTCTCGT.

**Generation of lentiviral KO vector**

Once the gRNA sequences were designed and ordered (Integrated DNA Technologies), they were cloned into the LentiCRISPR v2 vector (LentiCRISPR v2 was a gift from Feng Zhang; Addgene plasmid # 52961) (Sanjana et al., 2014). This is a dual-expression vector, expressing the CRISPR/CAS9 protein as well as the cloned gRNA sequence driven by the human U6 promoter. Briefly, DNA oligos representing the gRNA sequences are listed below, with overhangs compatible with the Esp3I restriction enzyme (bold, underlined) and an additional G added to the beginning of each gRNA, with a complementary C on the reverse oligo (bold, italics), for efficient transcription driven by the human U6 promoter.

| Integrin β5 gRNA 1.1 | CACCGGACCGAGAGGTGATGGACCGT |
|----------------------|-----------------------------|
| Integrin β5 gRNA 1.2 | AAACACGTTCCATCACTCTCGGTC |
| Integrin β5 gRNA 2.1 | CACCGCACCAGGAGTTGAGGACCG |
| Integrin β5 gRNA 2.2 | AAACCGTTCCATCACCTCGGC |
| eGFP gRNA 1.1       | CACCGCATGTGATCGCGCTTCTCGT |
| eGFP gRNA 1.2       | AAACACGAGAAGCCGCCCATGAC |
| Integrin α5 gRNA 1.1 | CACCGCTCAGTGGAGTTTTACCGGC |
| Integrin α5 gRNA 1.2 | AAACGGGCTAAAACCTCAGTACG |
| Integrin α5 gRNA 2.1 | CACCGTACGTGGAGTTTTACCGGC |
| Integrin α5 gRNA 2.2 | AAACGGGCAGTAAAACCTCACTAGC |
| Integrin αv gRNA 1.1 | CACCGATTCAATGGCTGGACCCGG |
| Integrin αv gRNA 1.2 | AAACCGCCGGTGCCAGCAATGATC |
| Integrin αv gRNA 2.1 | CACCGTACGTGGAGTTTTACCGGC |
| Integrin αv gRNA 2.2 | AAACCCGGGCGCCGGG |
| Integrin β3 gRNA 1.1 | CACCGCACCAGGAGTTGAGGACCG |
| Integrin β3 gRNA 1.2 | AAACCGTTCCATCACCTCGGC |
| Integrin β3 gRNA 2.1 | CACCGCATGTGATCGCGCTTCTCGT |
| Integrin β3 gRNA 2.2 | AAACACGAGAAGCCGCCCATGAC |

Next, the gRNA oligos stocks were diluted to 100 uM, and 1 uL of each gRNA pair was added to a T4 PNK reaction mixture (NEB, #M0201S) for a 10 uL reaction. The reaction was allowed to run in a thermal cycler to phosphorylate and anneal the oligos, according to the following program:

1. 37°C for 30 min
2. 95°C for 5 min
3. Decrease 5°C every minute until 25°C

To prepare the vector for cloning, 5 ug of LentiCrispr v2 vector were simultaneously cut with Fast Digest Esp3I (ThermoFisher, #FD0454) and dephosphorylated with Fast AP (ThermoFisher, #EF0651) for 30 min at 37°C and subsequently run on a 1.5% agarose gel and purified for cloning using the GeneJet Gel Extraction Kit (Thermofisher, #K0691).

To clone the annealed gRNA oligos into the vector, the oligos were diluted 1:200 in RNAase-free water (ThermoFisher, #4387937), and added to the quick ligation reaction mixture (NEB, #M2200S), along with 1 µL of the digested and dephosphorylated vector, and the reaction was allowed to proceed for 10 min at room temperature.

For bacterial transformation, 2 µL of the reaction was mixed with 50 µL of competent Stbl3 strain of Escherichia coli for 30 min on ice. The bacteria were then heat shocked for 45 s at 42°C and
immediately transferred to ice for 2 min. Then, 50 μL of the transformed bacteria were spread onto an LB/agar dish containing 100 μg/mL ampicillin and incubated at 37°C overnight.

The next day, single colonies were screened by colony PCR using the U6 promoter forward primer: GAGGGCCTATTTCAGATTTCCCATGATT and the corresponding reverse gRNA primers (gRNA x.2). Positive clones were selected to expand for plasmid purification and sequencing.

**CRISPR lentivirus production**

For functional lentiviral production, viruses were generated in 293T cells using the cloned LentiCrispr v2 plasmids, and two packaging plasmids: psPAX2 (psPAX2 was a gift from Didier Trono; Addgene plasmid # 12260) and VSVg. Briefly, 10 µg of cloned LentiCrispr V2, 5 µg of psPAX2, and 2 µg of VSVg were mixed in 1 mL serum-free/antibiotic-free DMEM in an 1.5 mL Eppendorf tube. 30 µL of X-treme Gene 9 (Roche, #06365787001) was added to the DNA mixture and gently mixed with the pipette tip. The mixture was allowed to sit for 45 min at room temperature. Next, the mixture was added drop-wise to a T75 flask containing 5 mL serum-free/antibiotic-free DMEM and 293T cells at ~85% confluence and slowly rocked for 30 s to evenly mix the DNA transfection mixture. The next morning, the serum-free media was removed from the 293T cell flasks, and 10 mL of fresh DMEM containing 10% FBS and 1% penicillin/streptomycin were added to each flask. Two days and 4 days post-transfection, the medium was collected and filtered through a 0.45 µm syringe filter (Millipore, #SLHV013SL) and then used immediately for viral infection of target cells, or stored at −80°C until needed.

**CRISPR lentiviral infection**

Target cells (naïve or desmoplastic fibroblasts) were seeded at ~40% confluence in 2 mL complete fibroblast media in a six-well plate. The following day, the target cells were infected with 2 mL of lentivirus for each corresponding CRISPR construct (eGFP or integrin gRNAs) in the presence of 10 μg/mL Polybrene (Santa Cruz, #sc-134220). As a control for the infection, cells were infected with a lentivirus overexpressing GFP, and the appearance of GFP-positive cells signified a successful infection. 24 hr later, the medium was replenished with fresh complete medium for each cell type. After 72 hr, puromycin selection (1 μg/mL for naïve fibroblasts, 2 μg/mL for desmoplastic fibroblasts) of the infected cells began. The selection process lasted between 7 and 10 days; cells were expanded, and the efficiency of CRISPR/CAS9 knockout was assessed by western blotting. The cell lines with the greatest degree of target protein knockout were used for subsequent experiments.

**SDS-PAGE/western blotting**

Briefly, various normal fibroblasts and CAFs were grown to confluency in six-well plates and were lysed in standard RIPA buffer. Lysates were then homogenized by sonication, allowed to rest on ice for 15 min, and centrifuged for 10 min at maximum speed in a microcentrifuge. Next, samples were diluted in 2x loading buffer (Bio-Rad, Hercules, CA), boiled for 3 min, and loaded onto 4–20% gradient gels (Bio-rad, Hercules, CA) and run at 70 volts for 2 hr. Next, gels were subjected to semi-dry transfer to PVDF membranes (Millipore, Billerica, MA) and blocked for 1 hr at RT in 5% milk in 0.1% TBST. Membranes were then incubated in the one of the following primary antibodies overnight at 4°C: rabbit polyclonal anti-αv-integrin (AB_2631308 (1:5000) (Mybiosource, San Diego, CA), rabbit monoclonal anti-α5-integrin (AB_2631309 (1:1000) (Abcam, Cambridge, MA), rabbit polyclonal anti-β5-integrin (AB_10806204 (1:1000) (Abcam, Cambridge, MA) or rabbit polyclonal anti-β3-integrin (1:1000) (AB_91119) (Millipore, Billerica, MA). The following day, membranes were washed in 0.1% TBST, 5 times for 5 min each. Next, membranes were incubated for 2 hr in anti-rabbit IgG-HRP secondary antibodies (Sigma, St. Louis, MO) in 5% milk in 0.1% TBST. Blots were then washed again five times/5 min each. Finally, Immobilon Western Chemiluminescent HRP substrate (Millipore, Billerica, MA) was added to the blots and protein bands were captured by film or Protein Simple Digital Imaging System (Protein Simple, San Jose, CA).

**Bioinformatics and statistics**

Two-tailed non-parametric Mann-Whitney tests were used to query experimental significances for all in vitro data, comparing control conditions to experimental ones independently. All in vitro results were presented as medians with interquartile range. Each PDAC-related in vitro experiment was...
performed at least three times, using one patient matched CAF and normal fibroblasts. For verification, these series of experiments were also conducted, using one additional pair of normal and activated fibroblasts from a non-related patient, two normal fibroblasts isolated from two additional non-related patients, and one tumor tissue which provided one additional non-related activated (desmoplastic) fibroblastic cell. All cells characterized as normal fibroblasts were verified for their phenotype and challenged with D-ECMs produced by CAFs isolated from three of the above described patients. These included a total of five different patient sources which included seven surgical samples. The RCC-related in vitro assessments were performed employing a combination of two patients-derived CAFs and normal fibroblasts from another two different sources. All the image analyses were conducted in at least ten images containing no less than three cells per region per experimental condition for each above-mentioned repetition.

Regarding statistics pertinent to the TMAs, to identify clinical and laboratory variables related to patient survival (OS, DSS, and RFS), univariate and multivariable analyses were performed by constructing decision trees using the CART methodology. Clinical and laboratory variables were considered as predictors of survival time and are listed in data uploaded to https://www.foxchase.org/sites/fccc/files/assets/cukierman_Franco-Barraza%20SMIA-CUKIE-Dec-2016.xlsx. The unified CART framework that embeds recursive binary partitioning into the theory of permutation tests was used. Significance-testing procedures were applied to determine whether no significant association between any of the clinical variables and the response could be stated, or whether the recursion would need to stop. Also, log-rank tests and univariate and multivariable Cox proportional hazards (PH) were used to correlate clinical and laboratory variables with survival; hazard ratios (with 95% confidence intervals) were calculated, as appropriate, for various comparisons. Goodness-of-fit of the PH model was evaluated based on Schoenfeld residuals. In order to account for potential batch effects, a ‘batch’ variable was included as an adjustment variable in all the analyses that were pertinent to the PDAC cohort. All tests were two-sided and used a significance level of 5% to test each hypothesis. Significant p-values in all figures were denoted by asterisks as follows: ****p<0.0001 extremely significant, ***p=0.0001–0.01 very significant, **p=0.01–0.05 significant and *p=0.05–0.10 marginally significant. Statistical analyses were performed using GraphPad Prism software, version 6.05 for Windows (La Jolla, CA) and the R packages survival and parity (www.r-project.org).

Acknowledgements

We thank Wafik S El-Deiry for providing critiques on the written manuscript and A Carson for proofreading. We also thank K Yamada (NIH), S Violette (Biogene Inc), D Sheppard (UCSF), M Humphries (UM-UK), and D Schlaepfer (UCSD) for providing reagents.

Additional information

| Funding      | Grant reference number | Author                                |
|--------------|-------------------------|---------------------------------------|
| National Cancer Institute | R01 CA113451            | Janusz Franco-Barraza Ralph Francescone Tiffany Luong Neelima Shah Raj Madhani Robert G Uzzo John P Hoffman Edna Cukierman |
| National Cancer Institute | Core Grant CA06927     | Janusz Franco-Barraza Ralph Francescone Tiffany Luong Neelima Shah Raj Madhani Gil Cukierman Essel Dulaimi Karthik Devarajan Brian L Egleston Emmanuelle Nicolas R Katherine Alpaugh |
Author contributions
JF-B, Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Writing—original draft, Writing—review and editing; RF, Resources, Data curation, Formal analysis, Validation, Investigation, Methodology, Writing—review and editing; TL, RMal, Data curation, Formal analysis, Validation, Methodology; NS, Validation, Investigation, Visualization, Methodology; RMad, Data curation, Validation, Investigation, Methodology; GC, Software, Visualization, Methodology; ED, Resources, Validation; KD, Data curation, Software, Formal analysis, Validation, Visualization, Methodology; BLE, Data curation, Software, Validation, Visualization, Methodology; EN, Formal analysis, Methodology; RKA, Resources, Methodology; RGU, JPH, Resources, Writing—original draft; EAG, Conceptualization, Visualization, Writing—review and editing; EC, Conceptualization, Data curation, Software, Formal analysis, Supervision, Funding acquisition, Visualization, Writing—original draft, Project administration, Writing—review and editing

Author ORCIDs
Janusz Franco-Barraza, http://orcid.org/0000-0003-3652-5311
Edna Cukierman, http://orcid.org/0000-0002-1452-9576

References
Achterberg VF, Buscemi L, Diekmann H, Smith-Clerc J, Schwengler H, Meister JJ, Wenck H, Gallinat S, Hinz B. 2014. The nano-scale mechanical properties of the extracellular matrix regulate dermal fibroblast function. Journal of Investigative Dermatology 134:1862–1872. doi: 10.1038/jid.2014.90, PMID: 24670384
Asano Y, Ihn H, Yamane K, Jinnin M, Tamaki K. 2006. Increased expression of integrin alphavbeta5 induces the myofibroblastic differentiation of dermal fibroblasts. The American Journal of Pathology 168:499–510. doi: 10.1016/j.ajpath.2006.04.1306, PMID: 16436664

Bever KM, Sugar EA, Bigelow E, Sharma R, Laheru D, Wolfgang CL, Jaffee EM, Anders RA, De Jesus-Acosta A, Zheng L. 2015. The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy. HPB 17:292–298. doi: 10.1111/hpb.12334, PMID: 25250696

Bijlsma MF, van Laarhoven HW. 2015. The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal. Cancer and Metastasis Reviews 34:97–114. doi: 10.1007/s10555-014-9541-4, PMID: 25566885

Binkley CE, Zhang L, Greenson JK, Giordano TJ, Kuck R, Misiek D, Hanash S, Logsdon CD, Simeone DM. 2004. The molecular basis of pancreatic fibrosis: common stromal gene expression in chronic pancreatitis and pancreatic adenocarcinoma. Pancreas 29:254–263. doi: 10.1097/00006676-200411000-00003, PMID: 15502640

Bissell MJ, Hines WC. 2011. Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nature 477:320–329. doi: 10.1038/nrm2328, PMID: 21383745

Bredfeldt JS, Liu Y, Conklin MW, Keely PJ, Mackie TR, Eliceiri KW. 2014. Automated quantification of aligned collagen for human breast carcinoma prognosis. Journal of Pathology Informatics 5:28. doi: 10.4103/2153-3539.139707, PMID: 25250186

Callahan JD, Burgess JL, Fornwald JA, Gaster LM, Harling JD, Harrington FP, Heer J, Kwon C, Lehr M, Mathur A, Olson BA, Weinstock J, Lapin NJ. 2002. Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5). Journal of Medicinal Chemistry 45:999–1001. doi: 10.1021/jm010493y, PMID: 11855979

Caswell PT, Chan M, Lindsay AJ, McCaffrey MW, Boettiger D, Norman JC. 2008. Rab-coupling protein coordinates recycling of alpha5beta1 integrin and EGFR1 to promote cell migration in 3D microenvironments. The Journal of Cell Biology 183:143–155. doi: 10.1083/jcb.200804140, PMID: 18383556

Choi W, Czemialk B, Ochoa A, Su X, Siefker-Radtke A, Dinney C, McConney DJ. 2014. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nature Reviews Urology 11:400–410. doi: 10.1038/nrurol.2014.129, PMID: 24960601

Clark K, Pankov R, Travis MA, Askari JA, Mould AP, Craig SE, Newham P, Yamada KM, Humphries MJ. 2005. A specific alpha5beta1 integrin conformation promotes directional integrin translocation and fibronectin matrix formation. Journal of Cell Science 118:291–300. doi: 10.1242/jcs.01623, PMID: 15615773

Conklin MW, Eickhoff JC, Riching KM, Pelhike CA, Eliceiri KW, Provenzano PP, Friedl A, Keely PJ. 2011. Aligned collagen is a prognostic signature for survival in human breast carcinoma. The American Journal of Pathology 178:1221–1232. doi: 10.1016/j.ajpath.2010.11.076, PMID: 21356373

Counter CM, Hahn WC, Wei W, Caddle SD, Beijersbergen RL, Lansdorp PM, Sedivy JM, Weinberg RA. 1998. Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. PNAS 95:14723–14728. doi: 10.1073/pnas.95.25.14723, PMID: 9843956

Cukierman E, Pankov R, Stevens DR, Yamada KM. 2001. Taking cell-matrix adhesions to the third dimension. Science 294:1708–1712. doi: 10.1126/science.1064829, PMID: 11721053

Dekker TJ, Charrehiili A, Smit VT, ten Dijke P, Kranenburg EM, van de Velde CJ, Nortier JW, Tollenaar RA, Mesker WE, Kroep JR. 2015. Disorganised stroma determined on pre-treatment breast cancer biopsies is associated with poor response to neoadjuvant chemotherapy: Results from the NEOZOTAC trial. Molecular Oncology 9:1120–1128. doi: 10.1016/j.molonc.2015.02.001, PMID: 25735561

Desmoul`ere A, Geinoz A, Gabbiani F, Gabbiani G. 1993. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. The Journal of Cell Biology 122:103–111. doi: 10.1083/jcb.122.1.103, PMID: 8314838

Dolberg DS, Bissell MJ. 1984. Inability of rous sarcoma virus to cause sarcomas in the avian embryo. Nature 309:552–556. doi: 10.1038/309552a0, PMID: 6203400

Dugina V, Fontao L, Chaponnier C, Vasiliev J, Gabbiani G. 2001. Focal adhesion features during myofibroblastic differentiation are controlled by intracellular and extracellular factors. The Journal of Cell Biology 153:1120–1128. doi: 10.1083/jcb.200004140, PMID: 11776839

Dvorak HF. 1986. Tumors: wounds that do not heal. similarities between tumor stroma generation and wound healing. The New England Journal of Medicine 315:1650–1659. doi: 10.1056/NEJM1986122531515206, PMID: 3537791

Erkan M, Kleej J, Gorbachevskii A, Reiser C, Mitkus T, Esposito I, Giese T, Büchler MW, Giese NA, Friess H. 2007. Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology 132:1447–1464. doi: 10.1053/j.gastro.2007.01.031, PMID: 17408641
Franco-Barraza J, Beacham DA, Amatangelo MD, Cukierman E. 2016. Preparation of extracellular matrices produced by cultured and primary fibroblasts. Current Protocols in Cell Biology 71:10.9.1–10.9.10. doi: 10.1002/cpcb.2 PMID: 27245425

Froeling FE, Feig C, Chelala C, Dobson R, Mein CE, Tuveson DA, Cleverson H, Hart IR, Kocher HM. 2011. Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-β-catenin signaling to slow tumor progression. Gastroenterology 141:1486–1497. doi: 10.1053/j.gastro.2011.06.047 PMID: 21704588

Garcia MN, Grasso D, Lopez-Millan MB, Hamidi T, Loncle C, Tomasiini R, Lomberk G, Porteu F, Urrutia R, Iovanna JL. 2014. IER3 supports KRASG12D-dependent pancreatic cancer development by sustaining ERK1/2 phosphorylation. Journal of Clinical Investigation 124:4709–4722. doi: 10.1172/JCI76037 PMID: 25205070

Goetz JG, Minguet S, Navarro-Lérida I, Lazcano JJ, Samaniego R, Calvo E, Tello M, Ostohe-Ibañez T, Pellinen T, Echarri A, Cerezo A, Klein-Santajo AT, Garcia R, Keely PJ, Sanchez-Mateos P, Cukierman E, Del Pozo MA. 2011. Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell 146:148–163. doi: 10.1016/j.cell.2011.05.040 PMID: 21729786

Goffin JM, Pittet P, Csucs G, Lussi JW, Meister JJ, Hinz B. 2006. Focal adhesion size controls tension-dependent recruitment of alpha-smooth muscle actin to stress fibers. The Journal of Cell Biology 172:259–268. doi: 10.1083/jcb.200506179 PMID: 16401722

Goreczny GJ, Ouwerkerk-Pecone JL, Olson EC, Krendel M, Turner CE. 2016. Hic-5 remodeling of the stromal matrix promotes breast tumor progression. Oncogene. doi: 10.1038/onc.2016.422 PMID: 27839716

Gupta V, Bassi DE, Simons JD, Devarajan K, Al-Saleem T, Uzzo RG, Cukierman E. 2011. Elevated expression of stromal palladin predicts poor clinical outcome in renal cell carcinoma. PLoS One 6:e21494. doi: 10.1371/journal.pone.0021494 PMID: 21738681

Handley DA, Arbeeny CM, Witte LD, Chien S. 1981. Colloidal gold–low density lipoprotein conjugates as membrane receptor probes. PNAS 78:368–371. doi: 10.1073/pnas.78.1.368 PMID: 6264440

Herberts S, Sawyer JS, Stauber AJ, Geuergueva I, Driscoll KE, Estrem ST, Cleverly AL, Desaih D, Guba SC, Benhadji KA, Slapak CA, Lahn MM. 2015. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Molecular Cancer Research 13:1486–1499. doi: 10.1172/JDRD.86621 PMID: 26309397

Hesler RA, Young JJ, Starr MD, Treboschi VM, Bernanke AG, Nixon AB, McCall SJ, White RR, Blobe GC. 2016. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3. Carcinogenesis 37:1041–1051. doi: 10.1093/carcin/bgw093 PMID: 27609402

Hinz B, Dugina V, Ballestrem C, Wehrle-Haller B, Chaponnier C. 2003. Alpha-smooth muscle actin is crucial for focal adhesion maturation in myofibroblasts. Molecular Biology of the Cell 14:2508–2519. doi: 10.1091/mbc.E02-11-0729 PMID: 12808047

Hinz B. 2016. Myofibroblasts. Experimental Eye Research 142:56–70. doi: 10.1016/j.exer.2015.07.009 PMID: 26129991

Horton ER, Humphries JD, Sturchby B, Jacquemet G, Ballestrem C, Barry ST, Humphries MJ. 2016. Modulation of FAK and Src adhesion signaling occurs independently of adhesion complex composition. The Journal of Cell Biology 212:349–364. doi: 10.1083/jcb.201508080 PMID: 26833789

Illé D, Furuta Y, Kanazawa S, Takeda N, Sobue K, Nakatsuji N, Fujimoto J, Okada M, Yamamoto T. 1995. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Journal of Biological Chemistry 270:39–50. doi: 10.1074/jbc.270.39.39 PMID: 865355

Ireland L, Santos A, Ahmed MS, Rainer C, Nielsen SR, Quarta V, Weyer-Czernilofsky U, Engle DD, Perez-Mancera PA, Coupland SE, Taktak A, Bogenrieder T, Tuveson DA, Campbell F, Schmid MC, Mielgo A. 2016. Chemoresistance in pancreatic cancer is driven by Stroma-Derived Insulin-Like growth factors. Cancer Research 76:6851–6863. doi: 10.1158/0008-5472.CAN-15-1201 PMID: 27742686

Jonasch E, Futreal PA, Davis JI, Bailey ST, Kim WY, Brugarolas J, Giaccia AJ, Kurban G, Paupe A, Friedman J, Zurita AJ, Rini BI, Sharma P, Atkins MB, Walker CL, Rathmell WK. 2012. State of the science: an update on renal cell carcinoma. Molecular Cancer Research 10:859–880. doi: 10.1158/1541-7786.MCR-12-0117 PMID: 22638109
Kalluri R, Zeisberg M. 2006. Fibroblasts in cancer. Nature Reviews Cancer 6:392–401. doi: 10.1038/nrc1877, PMID: 16572188

Khan Z, Marshall JF. 2016. The role of integrins in TGFβ activation in the tumour stroma. Cell and Tissue Research 365:657–673. doi: 10.1007/s00441-016-2474-y, PMID: 27515461

Klemm F, Joyce JA. 2015. Microenvironmental regulation of therapeutic response in cancer. Trends in Cell Biology 25:198–213. doi: 10.1016/j.tcb.2014.11.006, PMID: 25540894

Klingberg F, Chow ML, Koehler A, Boo S, Buscemi L, Quinn TM, Costell M, Alman BA, Genot E, Hinz B. 2014. Prestress in the extracellular matrix sensitizes latent TGF-β1 for activation. The Journal of Cell Biology 207:283–297. doi: 10.1083/jcb.201402006, PMID: 25332161

Klinghoffer RA, Sachsenmaier C, Cooper JA, Soriano P. 1999. Src family kinases are required for integrin but not PDGF signal transduction. The EMBO Journal 18:2459–2471. doi: 10.1093/emboj/18.9.2459, PMID: 10228160

Koay EJ, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Bhosele PR, Tamm EP, Crane CH, Javle M, Katz MH, Gottumukkala VN, Rozner MA, Shen H, Lee JE, Wang H, Chen Y, Plunkett W, Abbruzzese JL, et al. 2014. Transport properties of pancreatic cancer describe gemcitabine delivery and response. Journal of Clinical Investigation 124:1525–1536. doi: 10.1172/JCI73455, PMID: 24614108

Laeseke PF, Chen R, Jeffrey RB, Brentnall TA, Willmann JK. 2015. Combining in vitro diagnostics with in vivo imaging for earlier detection of pancreatic ductal adenocarcinoma: Challenges and solutions. Radiology 277:644–661. doi: 10.1148/radiol.2015140120, PMID: 26599925

Laklai H, Miroshnikova YA, Pickup MW, Collisson EA, Kim GE, Barrett AS, Hill RC, Lakins JN, Schlaepfer DD, Mow J, LeBlu VS, Roy N, Novitsky SV, Johansen JS, Poli V, Kalluri R, Iacobuzio-Donahue CA, Wood LD, Hebrok M, Hansen K, et al. 2016. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nature Medicine 22:497–505. doi: 10.1038/nm.4082, PMID: 270 89513

Langhans T. 1879. Pulsirende cavernose geschwiichter der miltz mit metastatischen knoten in der leber. Virchows Archiv 75:273–291. doi: 10.1007/bf02134657

Lee HO, Mullins SR, Franco-Barraza J, Valianou M, Cukierman E, Cheng JD. 2011. FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer 11:245. doi: 10.1186/1471-2407-11-245, PMID: 21668992

Lim ST, Chen XL, Tomar A, Miller NL, Yoo J, Schlaepfer DD. 2010. Knock-in mutation reveals an essential role for Src-based signals. American Journal of Physiology. Cell Physiology 299:C1361–C1369. doi: 10.1152/ajpcell.00370.2009, PMID: 19753624

Maga G, Clapero F, Panieri E, Panero V, Böttcher RT, Tseng HY, Saltarin F, Astanina E, Wolanska KL, Morgan MR, Humphries MJ, Santoro MM, Serini G, Valdembri D. 2016. PPFIA1 drives active α5β1 integrin recycling and controls fibronectin fibrillogenesis and vascular morphogenesis. Nature Communications 7:13546. doi: 10.1038/ncomms13546, PMID: 27876801

McDonald JA, Quade BJ, Broekelmann TJ, LaChance R, Forsman K, Hasegawa E, Akiyama S. 1987. Fibronectin's cell-adhesive domain and an amino-terminal matrix assembly domain participate in its assembly into fibroblast pericellular matrix. The Journal of Biological Chemistry 262:2957–2967

Meng XM, nikolic-Paterson DJ, lan HY. 2016. TGF-β: the master regulator of fibrosis. Nature Reviews Nephrology 12:325–338. doi: 10.1038/nrneph.2016.48, PMID: 27108839

Mintz B, Illmenes K. 1975. Normal genetically mosaic mice produced from malignant teratocarcinoma cells. PNAS 72:3585–3589. doi: 10.1073/pnas.72.9.3585, PMID: 10591474

Misraha R, Zhu L, Eckert RL, Simonson MS. 2007. TGF-β1 integrin recycling and matrix assembly control cell migration in pancreatic cancer. The Journal of Cell Biology 176:1168–1178. doi: 10.1083/jcb.200606171, PMID: 17135298

Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeka SG, Hoadley KA, Rashid NU, Tomczuk RA, Eaton SC, Chung AH, Smyla JK, Anderson JM, Kim HJ, Bentrem DJ, Talamonti MS, Iacobuzio-Donahue CA, Hollingsworth MA, Yeh JJ. 2015. Virtual microdissection identifies distinct tumor- and stroma-specific subsets of pancreatic ductal adenocarcinoma. Nature Communications 6:1168–1178. doi: 10.1038/ncomms5398, PMID: 26343385

Neuzillet C, Tijeras-Raballand A, Cohen R, Jaffiv E, Raymond E, de Gramont A. 2015. Targeting the TGF-β pathway for cancer therapy. Pharmacology & Therapeutics 147:22–31. doi: 10.1016/j.pharmthera.2014.11.001, PMID: 25444759

Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Hones D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, et al. 2009. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324:1457–1461. doi: 10.1126/science.1171362, PMID: 19460966

Oshima H, Nakayama M, Han TS, Naoi K, Ju X, Maeda Y, Robine S, Tsuichiya K, Sato T, Sato H, Taketo MM, Oshima M. 2015. Suppressing TGFβ signaling in regenerating epithelia in an inflammatory microenvironment is sufficient to cause invasive intestinal cancer. Cancer Research 75:766–776. doi: 10.1158/0008-5472.CAN-14-2036, PMID: 25687406

Özdemir BC, Pentecheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahler C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, Moses HL, Weaver VM, Maitra A,
Allison JP, LeBleu VS, et al. 2014. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25:719–734. doi: 10.1016/j.ccr.2014.04.005, PMID: 24856586

Paget S. 1889. The distribution of secondary growths in cancer of the breast. The Lancet 133:571–573. doi: 10.1016/S0140-6736(00)99115-0, PMID: 2673368

Pankov R, Cukierman E, Katz BZ, Matsumoto K, Lin DC, Lin S, Hahn C, Yamada KM. 2000. Integrin dynamics and matrix assembly: tensin-dependent translocation of alpha(S)beta(1) integrins promotes early fibroblast fibrillogenesis. The Journal of cell biology 148:1075–1090. doi: 10.1083/jcb.148.5.1075, PMID: 10704455

Petersen OW, Rannov-Jessen L, Howlett AR, Bissell MJ. 1992. Interaction with basement membrane serves to rapidly distinguish growth pattern of normal and malignant human epithelial cells. PNAS 89:9064–9068. doi: 10.1073/pnas.89.19.9064, PMID: 1384042

Principe DR, DeCant B, Diaz AM, Mangan RJ, Hwang R, Lowy A, Shetuni BB, Seekumkar BK, Chung C, Bentrem DJ, Munshi HG, Jung B, Grippo PJ, Bishehsari F. 2016. PDEF inhibits pancreatic tumorigenesis by attenuating the fibro-inflammatory reaction. Oncotarget 7:28218–28234. doi: 10.18632/oncotarget.8587, PMID: 27058416

Provenzano PP, Eliceiri KW, Campbell JM, Inman DR, White JG, Keely PJ. 2006. Collagen reorganization at the tumoral-stromal interface facilitates local invasion. BMC Medicine 4:38. doi: 10.1186/1741-7015-4-38, PMID: 17190588

Reed NI, Jo H, Chen C, Tsujino K, Arnold TD, DeGrado WF, Sheppard D. 2015. The αvβ1 integrin plays a critical in vivo role in tissue fibrosis. Science Translational Medicine 7:288ra279. doi: 10.1126/scitranslmed.aaa5094, PMID: 25995225

Rezkahaniha R, Agianniotis A, Schrauwen JT, Griffa A, Sage D, Bouton CV, van de Vosse FN, Unser M, Stergiopulos N. 2012. Experimental investigation of collagen waviness and orientation in the arterial adventitia using confocal laser scanning microscopy. Biomechanics and Modeling in Mechanobiology 11:461–473. doi: 10.1007/s10237-011-0325-z, PMID: 21744269

Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP, Tattersall IW, Westphalen CB, Kitajewski J, Fernandez-Barrena MG, Fernandez-Zapico ME, Iacobuzio-Donahue C, Olive KP, Stanger BZ. 2014. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25:735–747. doi: 10.1016/j.ccr.2014.04.021, PMID: 24856585

Roskelley CD, Bissell MJ. 1995. Dynamic reciprocity revisited: a continuous, bidirectional flow of information between cells and the extracellular matrix regulates mammary epithelial cell function. Biochemistry and Cell Biology 73:391–397. doi: 10.1139/o95-046, PMID: 8703411

Rönty MJ, Leivonen SK, Hinz B, Rachlin A, Otey CA, Kähäri VM, Carpén OM. 2006. Isoform-specific regulation of the actin-organizing protein palladin during TGF-beta1-induced myofibroblast differentiation. Journal of Investigative Dermatology 126:2379–2386. doi: 10.3183/jid.5700427, PMID: 16794588

Ryan MC, Kostner H, Gordon KA, Dunho S, Sutherland MK, Yu C, Kim KM, Nesterova A, Anderson M, McEachern JA, Law CL, Smith LM. 2010. Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75. British Journal of Cancer 103:676–684. doi: 10.1038/sj.bjc.6605816, PMID: 20664585

Sanjana NE, Shalem O, Zhang F. 2014. Improved vectors and genome-wide libraries for CRISPR screening. Nature Methods 11:783–784. doi: 10.1038/nmeth.3047, PMID: 25075903

Sasson AR, Wetherington RW, Hoffman JP, Ross EA, Cooper H, Meropol NJ, Freedman G, Pingpank JF, Eisenberg BL. 2003. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome. International Journal of Gastrointestinal Cancer 34:121–128. doi: 10.1385/IJGC:34:2:121, PMID: 15361645

Serini G, Bochaton-Piallat ML, Ropraz P, Geinoz A, Bochaton-Piallat ML, Ropraz P, Geinoz A, Borsi L, Zardi L, Gabbiani G. 1998. The fibronectin domain of ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta. The Journal of Cell Biology 142:873–881. doi: 10.1083/jcb.142.3.873, PMID: 9700173

Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Triac H, Collisson EA, Connor F, Van Dyke T, Kozlov S, Martin P, Tseng TW, Dawson DW, Donahue TR, Masamune A, Shimosegawa T, Apte MV, Wilson JS, Ng B, Lau SL, et al. 2014. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 159:80–93. doi: 10.1016/j.cell.2014.08.007, PMID: 25259922

Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D. 1992. Tenascin-C, a basement membrane macromolecule, is a powerful in vivo chemoattractant that regulates skin healing. Science 255:121–128. doi: 10.1126/science.1590961

Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, Autry C, Luzzio MJ, Cooper B, Metheny NW, Apte MV, Wilson JS, Ng B, Lau SL, et al. 2014. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 159:80–93. doi: 10.1016/j.cell.2014.08.007, PMID: 25259922

Sorman IM, DelGiorino KE, Greenberg PD, Hingorani SR. 2014. Stromal reengineering to treat pancreas cancer. Carcinogenesis 35:1451–1460. doi: 10.1093/carcin/bgu115, PMID: 24908682

Su G, Hodnett M, Wu N, Atakilit A, Kosinski C, Godzich M, Huang XZ, Kim JK, Franke JA, Matthy MA, Sheppard D, Pittet JF. 2007. Integrin alphavbeta5 regulates lung vascular permeability and pulmonary endothelial barrier function. American Journal of Respiratory Cell and Molecular Biology 36:377–386. doi: 10.1165/rcmb.2006-0238OC, PMID: 17079779
Tape CJ, Ling S, Dimitriadi M, McMahon KM, Worboys JD, Leong HS, Norrie IC, Miller CJ, Poulougiannis G, Laffenburger DA, Jørgensen C. 2016. Oncogenic KRAS regulates tumor cell signaling via stromal reciprocation. Cell 165:910–920. doi: 10.1016/j.cell.2016.03.029, PMID: 27087446

Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL. 1998. SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell 95:779–791. doi: 10.1016/S0092-8674(00)81701-8, PMID: 9865696

Wall SJ, Werner E, Werb Z, DeClerck YA. 2005. Discoidin domain receptor 2 mediates tumor cell cycle arrest induced by fibrillar collagen. Journal of Biological Chemistry 280:40187–40194. doi: 10.1074/jbc.M508226200, PMID: 16186104

Wang L, Pedroja BS, Meyers EE, Garcia AL, Twining SS, Bernstein AM. 2012. Degradation of internalized αvβ5 integrin is controlled by uPAR bound uPA: effect on β1 integrin activity and α-SMA stress fiber assembly. PLoS One 7:e33915. doi: 10.1371/journal.pone.0033915, PMID: 22470492

Webber JP, Sparry LK, Mason MD, Tabi Z, Brewis IA, Clayton A. 2016. Prostate stromal cell proteomics analysis discriminates normal from tumour reactive stromal phenotypes. Oncotarget 7:20124–20139. doi: 10.18632/oncotarget.7716, PMID: 26934553

Whatcott CJ, Han H, Von Hoff DD. 2015. Orchestrating the tumor microenvironment to improve survival for patients with pancreatic cancer: Normalization, not Destruction. The Cancer Journal 21:299–306. doi: 10.1097/PPO.0000000000000140, PMID: 26222082

Whitcomb DC, Pogue-Geile K. 2002. Pancreatitis as a risk for pancreatic cancer. Gastroenterology Clinics of North America 31:663–678. doi: 10.1016/S0889-8553(02)00004-3, PMID: 12134623

Wong YC, Cunha GR, Hayashi N. 1992. Effects of mesenchyme of the embryonic urogenital sinus and neonatal seminal vesicle on the cytodifferentiation of the Dunning tumor: ultrastructural study. Acta Anatomica 143:139–150. doi: 10.1159/000147240, PMID: 1598820

Wu L, Bernard-Trifilo JA, Lim Y, Lim ST, Mitra SK, Uryu S, Chen M, Pallen CJ, Cheung NK, Mielgo A, Stupack DG, Schlaeffer DD. 2008. Distinct FAK-Src activation events promote α5β1 and α4β1 integrin-stimulated neuroblastoma cell motility. Oncogene 27:1439–1448. doi: 10.1038/sj.onc.1210770, PMID: 17828307

Xu F, Liu C, Zhou D, Zhang L. 2016. TGF-β/SMAD Pathway and Its Regulation in Hepatic Fibrosis. Journal of Histochemistry & Cytochemistry 64:157–167. doi: 10.1369/0022155415627681, PMID: 26747705

Xu R, Boudreau A, Bissell MJ. 2009. Tissue architecture and function: dynamic reciprocity via extra- and intracellular matrices. Cancer and Metastasis Reviews 28:167–176. doi: 10.1007/s10555-008-9178-z, PMID: 19160017

Xu Y, Lu Y, Song J, Dong B, Kong W, Xue W, Zhang J, Huang Y. 2015. Cancer-associated fibroblasts promote renal cell carcinoma progression. Tumor Biology 36:3483–3488. doi: 10.1007/s13277-014-2984-8, PMID: 25613067

Zoppi N, Barlati S, Colombi M. 2008. FAK-independent αvβ3 integrin-EGFR complexes rescue from anoikis matrix-defective fibroblasts. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1783:1177–1188. doi: 10.1016/j.bbamcr.2008.03.003, PMID: 18405669